

Review Article

Impact of nutrition on long COVID

Subramanian Thangaleela, Chin-Kun Wang*

Department of Nutrition, Chung Shan Medical University, 110, Sec. 1, Jianguo North Road, Taichung City, Taiwan, China

ARTICLE INFO

Keywords:

Long COVID
Metabolic reprogramming
Immune dysregulation
Malnutrition
Nutritional intervention
Lactoferrin
Rehabilitation

ABSTRACT

Long COVID is characterized by a group of persistent symptoms following the acute SARS-CoV2 infection, which presented a multifaceted challenge to the healthcare systems all over the globe. The long COVID symptoms span various organ systems including the respiratory, cardiovascular, gastrointestinal, and neurological manifestations. Mitochondrial dysfunction and immune dysregulation play crucial roles in the long COVID pathophysiology. Recently nutritional intervention gained much attention in managing post-viral syndromes. Effective interventions like supplementation of omega-3 fatty acid, macro and micro nutrients, and vitamins help to reduce systemic inflammation and counteract muscle wasting. Other approaches like nutritional recovery, dietetic interventions, continuous nutritional care post-hospital discharge, nutritional rehabilitation programs, whole-diet approaches like Mediterranean diet, plant-based diet, and caloric optimization, improve overall functional recovery. Physical activity and exercise regimes have been shown to improve fatigue, dyspnea, and cognitive function. Tailored exercise regimes may promote safe rehabilitation. Certain ineffective interventions, such as non-personalized approaches, high dose of antioxidants, use of herbal products that are not clinically validated need to be addressed. Dietary interventions such as personalized nutritional counseling have been demonstrated to improve physical performance in long COVID patients. Further research is needed to refine protocols and identify optimal combinations of dietary and movement-based therapies to support the recovery of long-COVID patients. This narrative review focuses on the ongoing researches that reveals the intricate relationship between nutrition and long COVID recovery and also establishes effective protocols for nutritional care.

1. Introduction

SARS-CoV-2 virus with its 29.9 kb single-stranded RNA inserts into the human DNA and reprograms the larger size human DNA and changes the human cellular machinery to redirect the host macromolecules for its own survival and life cycle.¹ The virus particle reprograms the human DNA resulting in metabolic dysregulation of the host.² The SARS-CoV-2 virus favors the host metabolic pathways for its own survival and action by specifically interacting with the host cell targets. The interaction of the virus with the host impairs the host cell bioenergetics, immune response, and redox homeostasis.³ Thus, the SARS-CoV-2 virus induces human metabolic reprogramming/dysregulation (HMRD) in the infected human host and produces severe consequences.⁴ The virus-induced HMRD was not reduced even after the host declared virus free through negative RT-PCR tests. Long COVID or post-acute sequelae of SARS-CoV2 infection (PASC) affects numerous individuals who have recovered from COVID-19 infection.^{5,6} As a PASC, the survivors of COVID-19 showed certain clinical manifestations.^{7,8} The PASC includes

severe clinical symptoms that may cause metabolic dysfunctions in the cardiovascular, gastrointestinal (GI), central and peripheral nervous system (CNS/PNS), pulmonary, skeletomuscular, reproductive, and endocrine systems.^{9,10} The pathophysiology of long COVID involves persistent viral reservoirs, immune system dysregulation, tissue damage, and multi-organ failure.⁸ Onset of metabolic diseases like Type 2 diabetes mellitus (T2DM), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), dysautonomia, and postural orthostatic tachycardia syndrome (POTS) were found in PASC.^{9,11,12} The complexity of multisystem symptoms requires a broad scale perspective including multiple organ systems¹³ (Fig. 1). Long COVID diagnosis and management are highly challenging as its complications involve persistent viral reservoirs, dysregulation of immune system, and long-term tissue damage.¹⁴

2. Pathophysiology of long COVID and nutritional relevance

The SARS-CoV-2 invasion and infection induce human-pathogen interactions and result in host metabolic reprogramming (HMR), iron

* Corresponding author.

E-mail address: wck@csmu.edu.tw (C.-K. Wang).

Peer review under the responsibility of Editorial Board of Sports Medicine and Health Science

<https://doi.org/10.1016/j.smhs.2025.09.002>

Received 15 May 2025; Received in revised form 9 August 2025; Accepted 2 September 2025

Available online 5 September 2025

2666-3376/© 2025 Chengdu Sport University. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Abbreviation list

25-OHD	25-hydroxyvitamin D	IL	interleukin
ACE2	Angiotensin-converting enzyme 2	ITP	Immuno thrombocytopenia
AD	Alzheimer's disease	IU	International unit
ADAMTS-13	A disintegrin and metalloproteinase with thrombospondin motifs-13	LBP	lipopolysaccharide binding protein
Ang-2	Angiotensin-2	LF	Laoferrin
ARDS	Acute respiratory distress syndrome	M-CSF	Macrophage colony stimulating factor
BBB	Blood brain barrier	ME	Myalgic encephalomyelitis
BM	Bone marrow	MMP	Matric metallo proteinase
BMD	Bone mineral density	MSCs	Mesenchymal stem cells
BMI	Body mass index	mtDNA	mitochondrial DNA
BMSCs	Bone marrow stem cells	MUFAs	Mono unsaturated fatty acids
CCL	C-C motif chemokine ligand	NF-κB	Nuclear factor kappa B
CD4 ⁺ , CD8 ⁺	Cluster of differentiation 4+, 8+	NFL	Neurofilament light chain
CFQ	Cognitive failures questionnaire	NGF-β	Neurotrophic growth factor-β
CFS	Chronic fatigue syndrome	NLRP3	Nod like receptor protein family 3
CNS	Central nervous system	NMDARs	N-methyl-d-aspartate receptors
COPD	Chronic obstructive pulmonary disease	NO	Nitric oxide
CVDs	Cardio vascular diseases	OPG	Osteoprotegerin
CXCL	C-X-C motif chemokine ligand	Ox-LDL	Oxidised low-density lipoprotein
DCs	Dendritic cells	PASC	Post-acute sequelae of SARS-CoV2 infection
EBV	Epstein-Barr virus	PBD	Plant-based diet
EFAs	Essential fatty acids	PD	Parkinson's disease
eGFR	Effective glomerular filter rate	PF4	Platelet factor 4
EPCs	Endothelial progenitor cells	PNS	Peripheral nervous system
EPO	Erythropoietin	POTS	Postural orthostatic tachycardia syndrome
FAS	Fatigue assessment scale	PUFAs	Poly unsaturated fatty acids
FeRD	Iron (Fe)-redox dysregulation	RBD-SD-1	Recombinant receptor binding spike protein of SARS-CoV-2
GDNF	Glial derived neurotrophic factor	RCT	Randomized controlled trial
GFAP	Glial fibrillary acidic protein	ROS	Reactive oxygen species
GI	Gastro intestinal	SCFA	Short chain fatty acids
HADS	Hospital anxiety and depression scale	SOC	standard of care
HEP	Hepcidin	Syk	Spleen tyrosine kinase
HMRD	Human metabolic reprogramming/dysregulation	T2DM	Type 2 diabetes mellitus
HO-1	Heme oxygenase-1	TCA	Tri chloroacetic acid
hsCRP	High sensitive C-reactive protein	TGF-β	Transforming growth factor-beta
HSCs	Hematopoietic stem cells	TNF-α	Tumour necrosis factor-alpha
IBW	Ideal body weight	VEGF	Vascular endothelial growth factor
ICU	Intensive care unit	VWF	von Willebrand factor
IGFBP-4	insulin growth factor binding protein 4	VZV	Vvaricella-zoster virus
		WPB	Weibel-palade bodies

(Fe)-redox dysregulation (FeRD), altered mitochondrial function, which further leads to disturbance in cellular energy homeostasis, which cumulatively results in compromised host defense.¹⁵ The post-COVID syndrome can last for weeks, months, or years and affect various organs of the body, such as the heart, lungs, brain, muscles, joints, and blood vessels. The pathophysiology is complex, and a plethora of multiple overlapping mechanism leads to a weak immunologic response.¹⁶ SARS-CoV2 virus hijacked the host cell machinery and manifests mitochondrial dysfunction by disturbing mitochondrial membrane potential, mitochondrial permeability, pore opening, increased reactive oxygen species (ROS), and disturbs the redox homeostasis.^{17,18} In particular the ORF9b of SARS-CoV2 RNA evades host mitochondria and releases host mitochondrial DNA (mt-DNA) into the cytoplasm, which triggers the mt-DNA induced inflammasome and suppresses innate and adaptive immunity.¹⁹ Thus, the altered mitochondrial functions induce hyper-inflammation with cytokine storm and massive outburst of ROS.²⁰ Most significant mechanism of the virus induced hypoxia is termed as 'Warburg' effect, which involves the initiation of complex host pathogen interaction by SARS-CoV2 virus, alteration of mitochondrial function by disrupting the glycolysis and Tri chloroacetic acid (TCA) cycle, which

affect many metabolic pathways of amino acids, fatty acids, nucleotide and antioxidant synthesis, which in turn compromise host endocrinal, cardiovascular, gastrointestinal, pulmonary, reproductive and neuro-cognitive functions which are all requires high energy demand and mitochondrial oxygen consumption.^{21,22}

The viral residuals induce chronic phase of long COVID. This viremia and insufficient antibody contribute to the systemic inflammation, damage the CNS by endothelitis and disrupting blood brain barrier (BBB), thereby causing neuronal loss.^{23,24} SARS-CoV2 infection selectively targets the mitochondria of neurons, leading to brain fog and eventually impairing cognitive function.²⁵ The persistent immunologic response and viral induced cytokine storm rush the production of pro-inflammatory cytokines interleukin-7 (IL-7) and interferon-γ (IFN-γ).²⁶ The continuous activation of IL-6, IL-1β and tumour necrosis factor-α (TNFα) produce multiple organ specific effects such as cardiac dysrhythmias, neuroinflammation, neurodegeneration, renal injury, peripheral insulin resistance, bone resorption and hair loss in post-COVID.²⁷ Activation of NLRP3 inflammasome in addition to IL-18 and IL-1β affects cerebral function, and the NLRP3 inflammasome leads to the accumulation of amyloid-β peptides, resulting in neurodegenerative




Fig. 1. Post-Acute Sequelae of SARS-CoV2 infection (PASC) and its multi organ impact. GI-gastro intestinal; ARDS-acute respiratory distress syndrome; eGFR-effective glomerular filter rate; CVDs-cardio vascular diseases.

conditions.²⁸ The hyper-inflammatory condition causes loss of appetite, altered intestinal absorption, disturbed gut permeability, and malnutrition.^{29,30} The malnutrition induces inflammatory signalling and results in increased risk of microbial infections, dysbiosis.³¹ In individuals with long COVID, changes were found in hematological parameters such as anemia, lymphopenia, alterations in red blood cells, and elevated inflammatory markers like ferritin, D-dimer and IL-6.³² Other evidences suggest that some long COVID patients reported lower haemoglobin levels, enhanced D-dimer levels, and thrombocytopenia.^{33,34} The D-dimer assessment carried out in patients after a median of 94 days following COVID-19, it was found that D-dimer was elevated under long COVID conditions. The persistent elevation of D-dimer is recognized as a marker for coagulation activation that predisposes long COVID patients to thromboembolic complications. Thus, a significant proportion of long COVID patients show a hypercoagulable state with increased risk of thrombotic events.³³ Long COVID individuals show pronounced immune dysregulation, exhibited immune alterations, including T cell alterations, reduced CD4⁺, CD8⁺ memory cells, lack of naive T cells and B cells, elevated expression of type I and type III interferons, increased IL4, IL6 secreting CD4⁺ T cells at a median of 14 months after infection.³⁵

Long COVID patients develop more predictive symptoms such as fatigue, headache, shortness of breath, hoarse voice, and myalgia. These illnesses were found more prevalent among women, elderly people, and people with obesity.³⁶ Long COVID effects involve the cardiovascular system. Longitudinal studies report dial damage, heart failure in general population and in elderly people with co-morbidities.³⁷ High risk of muscle weakness and poor physical strength are observed in post-acute COVID-19 patients.³⁸ Other reports demonstrate cutaneous

manifestations and alopecia in patients.^{39,40} Neurologic complications, such as anosmia, cognitive and motor impairment,⁴¹ hyposmia, pain and insomnia, hypometabolism in brain regions orbital gyrus, olfactory gyrus, temporal lobe, amygdala, hippocampus, thalamus, pons/medulla rain stem, and cerebellum.⁴²

3. Bone marrow and stem cell exhaustion in long COVID

SARS-Cov-2 infection has been recognized for its direct and indirect effects on bone health, driven by the cellular and inflammatory mechanisms. The post-acute sequelae of SARS-CoV-2 infection changes the bone health by affecting bone marrow (BM) cells, altering bone structure, and number of osteoclast cells. The inflammatory cytokine storm triggered by the virus stimulate osteoclast activity and produce bone loss. Hypocalcemia, reduced bone mineral density (BMD), and prevalence of vertebral fractures were become more prevalent after COVID infection.⁴³ Epidemiological data indicated that in several cases, skeletal health was also significantly affected by SARS-CoV-2 infection. The presence of ACE2 receptors on bone cells leads to direct infection of virus in BM cells. In addition to ACE2 receptors, virus remodels the bone, and affects the osteoclast through ACE2/Ang-(1-7)/MasR axis.⁴⁴ The recombinant receptor binding spike protein of SARS-CoV-2 (RBD-SD-1) was used to study the SARS-CoV-2 virus tropism in 33 kinds of human tissues, among all the tissues, the RBD-SD-1 probe was strongly binded with BM cells. This indicates that SARS-CoV-2 virus interactions with BM niche, especially hematopoietic stem cells (HSCs).⁴⁵ The BM stem cell exhaustion arises from the acute infection, and immune responses elicited by vaccination is a significant contributor to COVID

pathophysiology. SARS-CoV-2 infection affects the BM microenvironment, causing damage to HSCs and endothelial progenitor cells (EPCs).⁴⁶ COVID virus infects the EPCs directly and disrupts the homeostasis haemoglobin, thus the red blood cells become a direct target of covid virus.⁴⁷ COVID infection alters and significantly affects blood cells and BM of patients, resulting in conditions such as cytopenia, pancytopenia, hemophagocytosis, and BM necrosis. The immunomodulatory therapies help in minimizing the hyperinflammation condition of long COVID. Mesenchymal stem cells (MSCs) are effectively used in immunomodulatory therapies due to its anti-inflammatory and tissue-regenerative properties.⁴⁸

The effect of SARS-Cov-2 virus on blood cells indicates that the viral infection involves the BM as its the place of production and maturation of blood cells. Hence investigating the effects of virus on BM is necessary.⁴⁹ In long COVID context, the bone marrow stem cell exhaustion arises due to depletion and functional disturbance in stem cells of bone marrow. The inflammatory milieu arises from viral infection attenuates the differentiation capacities of bone marrow stem cells (BMSCs), thus causing the exhaustion of HSCs and MSCs. Bone abnormalities in COVID patients are common due to its direct infection of bone marrow cells. The bone abnormalities can be due to the viral particle onto ACE2 receptors on CD14⁺ monocytes, a precursor to osteoclasts.⁴⁴ SARS-CoV-2 virus cause aseptic necrosis of the bone by binding to ACE2 receptors of endothelial cells, lungs, other tissues, and penetrates the endothelial cells of the vessels and produce vascular damage by inflammatory syndrome and coagulation.⁴⁹ The acute inflammatory conditions induce collagen changes and affect bone health.⁵⁰ Another contributing factor is the hypoxic condition induced by viral infection. The low oxygen level in tissues produce bone resorption by increasing osteoclasts. Additionally, the bone mineralization gets affected through acidosis. Hypoxia upregulates erythropoietin (EPO), glycoprotein, which suppresses the formation of bones. Other conditions, such as anemia and chronic obstructive pulmonary disease (COPD) also produce hypoxic conditions and further impact the bone health which, reduce BMD and increase the risk of bone fractures.⁴³ Direct invasion of SARS-CoV-2 in HSCs induces the mechanism of hypoxia or hyperinflammation in hematopoietic system and leads to stress in erythropoiesis, lymphopenia, neutrophilia and thrombocytopenia.⁵¹ On the other side, not only the COVID infection, but the vaccination also developed BM suppression, pancytopenia, and thrombocytopenia. A 74-years old male reportedly developed BM suppression seven days after receiving Pfizer SARS-Cov-2 vaccine.⁵²

COVID vaccines showed side effects such as mild to severe anaphylaxis and immuno thrombocytopenia (ITP)⁵³ that targets the immune system, and destroys the platelets produced by megakaryocytes in BM. And the function of platelets in inflammatory signalling and preventing microbial invasion are slowed down during COVID infection. The autoantibodies arising by COVID infection also trapped the platelets and destroyed it. In some cases, COVID-19 increased immature platelets and increased coagulation.⁴⁹ To control the immune dysfunction, non-pharmacological therapies can effectively halt the immune dysregulation. Immunomodulation by using stem cells can be an effective option. MSCs are now promising and efficient candidates in pre-clinical studies. MSC transplantation in severely ill COVID patients significantly improved the pulmonary functions.⁵⁴ Most importantly, MSCs are ACE-2 negative genetically, and unlikely to encourage the viral attachment in transplanted cells. When critically ill COVID-19 patients treated with MSCs derived from human umbilical cord, it improved functional outcomes. Hence, the MSCs can help modulating the immune response in a positive way.⁵⁴ BMSC exhaustion is a vital mechanism in long COVID that affects the BM derived stem cells, particularly HSCs. These stem cell populations undergo persistent activation during COVID infection, resulting in impaired haematopoiesis, and chronic inflammation. Long COVID condition altered the hematologic functions, which is a reflection of underlying BM exhaustion. In other scenarios, vaccine-induced BM exhaustion also occurs. To investigate the disability and reversibility of BMSC function in long COVID conditions, further pre-clinical and

clinical research is required to analyse the possibilities of regenerative therapies using stem cell restoration.

4. Biomarkers of long COVID

As the exact mechanism and symptoms of long COVID still remain unknown. Identifying the biomarkers is currently of greater scientific focus. Researchers work on biomarkers for long COVID to evaluate most frequent symptoms like immunological and inflammatory conditions, endothelial and vascular dysfunction, and also the metabolic and clotting abnormalities.⁵⁵ Blood-based biomarkers are significantly important indicators, or act as therapeutic targets for diagnosing and treating long COVID. A systemic review carried out by Lai and team, focused on the blood-based biomarkers associated with long COVID symptoms and progression, identified about 113 biomarkers categorised under 6 biological sections including cytokines/chemokine, biochemical, vascular, neurological, acute phase proteins, and other markers.⁵⁶ Acute phase proteins, including albumin, CRP, ferritin, fibrinogen; biochemical markers, including 1-methylnicotinamide, β -glucan, glutamine/glutamate ratio, indole 3-acetic acid, L-Cysteine, Lactate dehydrogenase, L-glutamine, L-methionine, Pipecolic acid, Quinolinic acid, S-Sulfofocysteine, Taurine, Tryptase, Cytokine; and chemokine markers, such as, C-C motif chemokine ligand (CCL) 2–7, CCL 19, CCL 20, CCL 23, C-X-C motif chemokine ligand (CXCL) 1, CXCL9-11, G-CSF, GM-CSF, IFN- α , β , γ , IL-1 α , IL-1 β , IL-2, IL-4, IL-6, IL-7, IL-10, IL-10R β , IL-12 β , IL-13, IL-17, IL-18, IL-33, IP-10, Macrophage colony stimulating factor (M-CSF), tumour growth factor- α (TGF- α), TGF- β , TNF- α , TNF- β ; neurological markers like glial derived neurotrophic factor (GDNF), glial fibrillary acidic protein (GFAP), neurotrophic growth factor- β (NGF- β), Neurofilament light chain (NFL), Neurotrophin-3; vascular markers, including Ang-2, D-dimer, Factor VIII, Matric Metallo Proteinase-1,9 (MMP 1,9) vascular endothelial growth factor (VEGF), von Willebrand factor (VWF) antigen, VWF propeptide; and other markers like Artemin, Caspase 8, Cystatin-5, Cystatin C, insulin growth factor binding protein 4 (IGFBP-40), lipopolysaccharide binding protein (LBP), miRNA21, OPG, Sirtuin 2 and zonulin.⁵⁶ In order to monitor and treat long COVID symptoms, studying the clinically relevant circulating biomarkers has become essential to understand patients' clinical condition. Increased levels of NFL and GFAP in serum are signs of neuronal damage or progressing neurodegenerative diseases like Alzheimer's disease (AD),⁵⁷ or Parkinson's disease (PD).⁵⁸ The immune response elicited in long COVID patients results in higher levels of pro-inflammatory cytokines/chemokines, including IL-4, IL-6, IL-7, TNF- α , C-C motif chemokine ligand 2 (CCL-2), CRP, and ferritin. Elevated levels of NFL, vascular endothelial growth factor (VEGF), and reduced haemoglobin levels are marked evidence for worsening long COVID symptoms.⁵⁵ During the convalescent phase of COVID-19, the common inflammatory and immunological markers such as IL-6, TNF- α , antiphospholipid antibodies, and lupus anticoagulant were found in patients.⁵⁹ Long COVID may be related to microvascular inflammation causing clumping and clotting of red blood cells and platelets, thrombotic complications. Bellone et al. evaluated the levels of VWF, and Factor VIII in PASC/long COVID patients. Their results show that VWF and factor VIII levels were found elevated for at least 2 years in patients with long COVID symptoms.⁶⁰ These alterations promote pulmonary micro thrombosis and continuous endothelial activation. Another study reviewed the VWF/A Disintegrin and Metalloproteinase with Thrombospondin Motifs-13 (ADAMTS-13) axis imbalance and endotheliopathy in long COVID and its relevance to dysregulated angiogenesis, immuno thrombosis, sustained endothelial and coagulation activation. Analysis of 50 patients during their convalescent phase showed elevated VWF-ADAMTS-13 ratio, platelet factor 4 (PF4), Weibel-Palade bodies (WPB), Angiotensin-2 (Ang-2), and Osteoprotegerin (OPG) proteins.⁶¹ WPB found in endothelial cells store and release important VWF, Ang-2, PF 4, and P-selectin molecules responsible for inflammatory responses.⁶¹ Neurological long COVID sequelae accelerated by IL-6, TNF- α , and CRP, which induce immune cells and activate neuroinflammation. The proteins responsible for

maintaining neuronal stability of axons and astrocytes NFL, and GFAP are biomarkers of neuronal damage.^{62,63} COVID patients with headaches and persistent neuropathic pain showed elevated serum levels of NFL and GFAP.^{64,65} Long COVID patients with pulmonary fibrosis showed elevated IL-6, TNF- α , and TGF- β .⁶⁶ A cross-sectional Mount Sinai-Yale long COVID (MY-LC) study involving 275 participants showed decreased systemic serum cortisol, and serum galectin 1 concentration acts as a significant predictor of long COVID. In addition, significant immunological differences were found. The populations of non-conventional monocytes, double-negative B cells, conventional dendritic cells, and memory CD4⁺ T cells were decreased. Long COVID individuals had higher levels of antibodies to SARS-CoV-2, Epstein-Barr virus (EBV), and varicella-zoster virus (VZV) antigens, and marked changes in circulating cytokines and hormones also noted.³⁵ Oxidised low-density lipoprotein (ox-LDL), increased fungal cell wall polysaccharide (1,3)- β -d-glucan, intestinal permeability marker zonulin were found in long COVID individuals, and these markers clearly show the alteration in gut integrity, tight junction permeability, and fungal translocation. Increased ox-LDL, a major contributor to atherosclerosis stimulates the inflammation leading to prolonged expression of TNF- α and IL-6 genes. The inflammation induced by ox-LDL activates TLR-4 dependent inflammasome.^{67,68} The translocation of β -d-glucan in the plasma of long COVID individuals directly proportional to inflammation and elevated levels of host metabolites, which in turn activate the *N*-methyl-d-aspartate receptors (NMDARs) and tryptophan catabolism pathway that has been associated with neurotoxic effects through higher levels of quinolinic acid and S-Sulfocysteine.⁶⁹ The translocated β -d-glucan also induces inflammasome through by activating spleen tyrosine kinase/Nuclear factor kappa B (Syk/NF- κ B) pathway. As a consequence of this, PASC contributes to the elevated and sustained levels of immune activation and inflammation.⁶⁹ The long COVID management and patient care require knowledge about long COVID biomarkers and symptom management approaches. The biomarkers may serve as diagnostic and prognostic markers (Table 1).

5. Underlying mechanisms of nutrients

A complex interplay exists between nutrients and immune functions in long COVID. Various inflammatory mediators, pro-, anti-inflammatory cytokines are being regulated by specific nutritional components. Nutrients and dietary patterns influence the regulation of cytokines and chemokines. Large amount of pro-inflammatory cytokines is released both in acute and chronic COVID conditions. Minerals, co-enzymes, and vitamins have a significant impact on the inflammatory response triggered by COVID virus. Supplementation with vitamins A, B1, B2, B3, B5, B6, B7, B9, B12, C, D, E, and K controls the TNF- α , IL-1 β , and IL-6 release.⁷⁰ In COVID-infected individuals, health is compromised due damage in the gastrointestinal tract, liver, and vasculature that results in impaired nutrient absorption, which affects metabolic processes. These disruptions are due to the immune dysregulation, chronic inflammation, gut microbial imbalances. Long-COVID condition involves virus-induced metabolic reprogramming resulting in mitochondrial dysregulation, oxidative stress, reduced host defensive mechanisms, altered signalling pathways. These reasons are collectively suppressing the host appetite and reduce the intake, delay the recovery and worsen the nutritional deficiency.⁷¹ Proteins are essential for repairing and maintaining cellular structures, including mitochondria. The lack of amino acids like L-carnitine in long COVID causes dysregulation in fatty acid transport to mitochondria, β -oxidation and ATP production. L-carnitine is an immune regulator that helps controlling pro-inflammatory IL-6, IL-1, and TNF- α .⁷² A diet with optimal carbohydrate to fat ratio is essential to improve mitochondrial performance through glucose metabolism.⁷³ Long chain omega-3 PUFAs favourably support immune function, inflammation, and oxidative stress at different stages of COVID infection. In case of long COVID, omega-3 PUFAs and their metabolites enhance the process of clearing chronic inflammation, restoring homeostasis of tissues.⁷⁴

Table 1
Long COVID biomarkers.

Category	Bio markers	References
Pro-inflammatory markers	IL-2, IL-6, IL-7, IL-12 β , IL-17, IL-18, IL-33 TNF- α , TNF- β , IFN- α , β , γ CCL2-7, CCL 19, CCL 20, CCL 23, CXCL 1, CXCL9-11 IL-1 α , 1 β , IP-10	56,66
Anti-inflammatory markers	IL-4, IL-10, IL-10R β , IL-13, TGF- β	66
Blood based markers	CRP, Ang-2, D-dimer, Factor VIII, VWF antigen, VWF propeptide	56,61
Protein markers	G-CSF, GM-CSF, M-CSF, GDNF, GFAP, NGF- β , NFL, Neurotrophin-3, MMP-1, MMP-9, VEGF, Artemin, Caspase 8, Cystatin-5, Cystatin C, IGFBP-4, LBP, miRNA21, OPG, SIRT 2 and zonulin, Trypsinase	56,61,63
Biochemical markers	1-methylnicotinamide, β -glucan, glutamine/ glutamate ratio, indole 3- acetic acid, L- Cysteine, Lactate dehydrogenase, L- glutamine, L-methionine, Pimelic acid, Quinolinic acid, S-Sulfocysteine, Taurine	56,69
Signalling pathways	Syk/NF- κ B pathway, NF- κ B signalling, NMDARs and tryptophan catabolism pathway, NLRP3 inflammasome pathway	67,68

IL-interleukin; TNF- α , β -tumour necrosis factor-alpha, beta; IFN- α , β , γ -interferon-alpha, beta, gamma; CCL- C-C motif chemokine ligand; CXCL- C-X-C motif chemokine ligand; IP-10- interferon gamma induced protein; TGF- β – tumour growth factor beta; CRP- c-reactive protein; Ang-2- Angiotensin-2; VWF- Von Willebrand factor; G-CSF- granulocyte colony stimulating factor; , GM-CSF- granulocyte-macrophage colony stimulating factor, M-CSF- macrophage colony stimulating factor, GDNF- glial derived neurotrophic factor; GFAP- glial fibrillary acidic protein; NGF- β -neuronal growth factor beta; NFL- neurofilament light chain; MMP-1, 9- matrix metalloproteinase 1,9; VEGF- vascular endothelial growth factor; IGFBP-4- insulin growth factor binding protein 4; LBP-lipoplysaccharide binding protein; OPG- Osteoprotegerin; NF- κ B -Nuclear factor kappa B; Syk/NF- κ B -Spleen tyrosine kinase/Nuclear factor kappa B; NLRP3-nod like receptor protein family 3.

A randomized controlled trial studied mitochondria-derived vesicles and inflammatory profile of adults with long COVID after supplementation with red beetroot juice for 14 days. The study showed remarkably reduced serum levels of IL-1 β , IL-8, TNF- α , without affecting mitochondrial circulating markers. Polyphenols from red beetroot are naturally potential antioxidants capable of regulating inflammatory profiles in patients with long COVID.⁷⁵ Nutritional components like phytochemicals enhance mitochondrial biogenesis and control oxidative damage. Dietary components are significantly restoring the mitochondrial function. For example, curcumin is reported to have positive effect on both COVID-19 and long COVID.⁷⁶ Intake of iron is useful in reducing inflammation, fatigue and dyspnea, and also improve immune response to vaccination.⁷⁷ Zinc helps inhibiting coronavirus RNA polymerase activity invitro and viral replication in cultures cells.⁷⁸ Magnesium exhibits anti-inflammatory properties, and helps in regulating innate and adaptive immune responses. Magnesium sulfate supplementation reduced inflammatory response, and oxidative stress by controlling chemokines and cytokines such as IL-1, IL-6, IL-8, TNF- α , and CRP.^{79,80} Supplementation of amino acids and micronutrients like magnesium, iron, and selenium significantly reduced CRP and IL-6.⁸¹ Vitamins, in particular vitamin D have been highlighted for modulating mitochondrial dynamics and enhanced oxidative stress responses. By improving redox status, the interventions with vitamins and polyphenols mitigate systemic inflammation and thereby address components of long COVID. Probiotic supplementation helps restore gut microbiota. Re-establishing gut microbiome positively influences the systemic inflammation, mitochondrial health and reduces immune dysregulation.⁸² Vitamins reduce inflammatory and oxidative stress markers like IL-6, TNF- α , sTNF-RI, sCD163, oxLDL via regulating gut permeability and systemic inflammation.⁸³ Overall diets rich in both macro- and

micronutrients can significantly support mitochondrial health, reduce oxidative stress, and improve immune responses in long COVID patients.

6. Functional role of nutrient components in managing long COVID

The long COVID syndrome is characterized by malnutrition, loss of fat free mass and low-grade inflammation, fatigue, sleep disturbances, dyspnea, joint pains, anxiety, chest pain, brain fog, cognitive dysfunction, thromboembolism, loss of hair, and chronic kidney disease.⁸⁴ The nutritional assessment and status including the evaluation of dietary intake, anthropometric measures and body composition has become essential to manage the long COVID symptoms. The supplementation of nutrition using proper guidelines tailored by nutritionists has become a prominent strategy to ensure patients' recovery.⁸⁵ Malnutrition has a high impact on the recovery of patients from long COVID syndrome. Nutritional intervention plays a crucial role in managing long COVID by alleviating symptoms, and improving physical and mental well-being.⁸⁵ Nutritional status has emerged as a pivotal factor in modulating immune response and mitigate the pathological process on long COVID. Improving the nutritional status through targeted supplementation and dietary modifications could aid in restoring immune balance and promote recovery.²⁶ Vitamin D deficiency may exacerbate chronic inflammation and impair glycemic control,⁸⁶ and also controls the pro-inflammatory cytokines, induces macrophages and produces anti-inflammatory cytokines to reduce the risk of acute respiratory distress syndrome (ARDS).⁸⁷ Vitamin D deficiency may contribute to the exacerbation of long COVID. Its immunomodulatory properties are believed to influence the persistence of PASC.⁸⁸ Nutritional interventions that include antioxidants and anti-inflammatory nutrients can help counteract oxidative stress and modulate the pro-inflammatory cytokine release which are central to the long COVID pathogenesis.²⁶ Though the prohormone is mainly obtained through sun exposure to a great extent, a minor contribution can be taken over through diet. 25-hydroxyvitamin D (25OHD), an inactive precursor of vitamin D is reported to be higher in meat and fish eaters in comparison to vegetarians and vegans.⁸⁹

The most important aspect of nutritional management is early screening and assessment for malnutrition. The health consequences in PASC require host-system targeted nutritional interventions such as immune-modulators, antioxidants, micro-, macro-nutrient metabolic optimizers, natural plant-based anti-inflammatories to manage PASC.⁴ The interventions include prophylactic nutritional support, individualized calorie and protein targets, specific micronutrient supplementation such as vitamin D, vitamin C, zinc, omega-3-fatty acids to support immune functions and reduce inflammation.⁹⁰ Sarcopenia, a kind of progressive and skeletal muscle disorder, is known to occur as a long COVID complication leading to loss of muscle mass, muscle strength, physical functioning especially in older patients. A minimum daily protein requirement of 0.83 g of good quality protein/kg body weight per day is required for a healthy subject and supplementation with β -hydroxy- β -methyl butyrate or creatinine in the form of balanced diet support the muscle mass restoration and enhance fast physical recovery.⁹¹ A systemic scoping review involving review of literature studies with participants aged 18 years of older with long COVID, who underwent a nutritional intervention highlighted that nutritional intervention is important in rehabilitation programs and to address malnutrition and muscle wasting.⁹²

6.1. Macronutrients and micronutrients

The amount of protein intake directly impacts the immune system. The post COVID-19 patients' protein requirements are suggested to be higher to reduce sarcopenia and muscle mass reduction.⁹³ Long COVID patients are recommended to include high-quality plant and animal proteins about 15–30 g protein per meal based on ideal body weight

(IBW), ensuring the intake of all essential amino acids.⁹⁴ Restriction of carbohydrates and sugar may exacerbate viral outcomes, because the pathogen-clearing CD4⁺ and CD8⁺ T cells require energy from glucose and anaerobic glycolysis.⁹⁵ On the contrary higher carbohydrate increase the respiratory quotient. High-glycemic index inducing carbohydrates such as white flour, refined sugar result in overload of the mitochondria and produce more free radicals. Even a small rise in glycemic index could cause immediate inflammatory response, increased cytokines, C-reactive protein (CRP), increased levels of TNF- α and IL-6.⁹⁶ Hence, maintaining a balanced carbohydrate diet is crucial both during and post-COVID. Choosing a wise amount of carbohydrate like high quality carbohydrates low glycemic load foods such as vegetables, fruits, nuts, seeds, whole grains, these do not induce post-prandial inflammatory responses. Based on the patient's glycemic control and ventilator dependency usually 30%–50% non-protein calories have been required, and the glucose must not exceed 5 mg·kg⁻¹·min⁻¹.⁹⁷ Dietary fibres are complex carbohydrates and significantly important to reduce hs-CRP, IL-6, TNF- α . Taking whole grains supports gut microbiome, lowers gut inflammation and increased SCFA production.⁹⁶ Regarding fat intake, the adequate intake of essential fatty acids (EFAs), correct proportion of poly unsaturated fatty acids (PUFAs) and mono unsaturated fatty acids (MUFAs) within 30%–45% of calories from fats could be useful in patients with pneumonia and ARDS occurred due to COVID-19.⁹⁸ Fats are essential for absorption of fat-soluble vitamins (A, D, E, and K), immune function and inflammation reduction.⁹⁰

Micronutrients vitamin A, C, D, E, B6, B12, folate, iron, zinc, selenium, copper, and magnesium support the host-viral resistance, innate immune activation.⁹⁹ Micronutrients include 12 types of vitamins, macro-minerals and trace elements and certain ultra trace elements like nickel and boron. Vitamin A is important for epithelial cell morphology, formation of healthy mucus layers in respiratory tract and intestine, for mucus secretion and to improve antigen specific and non-specific immune functions.¹⁰⁰ Low vitamin A individuals showed increased risk of developing lung dysfunction and respiratory disease.¹⁰¹ Vitamins A, C, D, E, Zn, Fe, Cu, and Se regulate IFN production, which is crucial for anti-viral innate immune response and antiviral cytokines, to induce inflammatory response and also for mitochondrial antiviral signalling.⁹⁹ Vitamin D regulates immune cells neutrophils, natural killer cells, macrophages, monocytes, production of pro- and anti-inflammatory cytokines, differentiation and function of T cells, and production of viral specific antibodies⁹⁹ (Fig. 2). Preliminary trial using vitamin K2/D3 in treating long COVID found to efficiently reduce long COVID symptoms. Intake of vitamin K2/D3 improved systemic inflammatory markers and gut dysfunction.⁶⁸ Vitamin D helps in the regulation of dendritic cells (DCs), monocytes/macrophages, T cells, and B cells. It also promotes the synthesis of antimicrobial peptides and enhances the production of anti-inflammatory cytokines like IL-10 and suppresses TNF- α . On the other hand, vitamin K reduced IL-6. Vitamin K3 and D3 have demonstrated anti-inflammatory effects. Treatment with vit K2/D3 supplementation found reduce long COVID index and symptoms.⁶⁸

Although the exact pathophysiology Vitamin K2/D3 helps improving long COVID symptoms by attenuating systemic inflammation. A Randomized clinical trial (RCT) study carried out in adults experiencing ≥ 2 moderate long COVID symptoms shows that daily intake of 240 μ g vitamin K2 and 2 000 IU vitamin D3 for 24 weeks reduced long COVID index by 7.1% and reduced the ox-LDL, inflammatory markers, serum TNF R1 and serum CD163 and fungal translocation marker 1,3- β -d-glucan. This study concludes that daily intake of vitamins K2 and D3 improved the RECOVER long COVID index, gut and inflammatory markers.⁶⁸ Vitamin C helps in production of IFNs, enhancing serum complement proteins and induce proliferation of T cells, maintain redox homeostasis.¹⁰² Vitamin A helps regulate natural killer cells and macrophages, downregulates IL-2, TNF- α and aids in antibody production by B cells.¹⁰³ Various active forms of vitamin A including retinol, retinal, and retinoic acid promote various important biological functions. Retinoic acid helps in promoting immediate response to invasion of




Fig. 2. The essential macronutrients-carbohydrates, proteins, fats and dietary fibres and their role in supporting immune function and overall well-being in individuals with Long COVID sequelae. CD4⁺, CD8⁺ - cluster of differentiation 4+, 8+; hs-CRP-high sensitive C reactive protein; IL-interleukin; TNF- α -tumour necrosis factor-alpha; SCFA-short chain fatty acids; NO-nitric oxide; NF κ B -Nuclear factor kappa B.

pathogen, activates natural killer cells.¹⁰⁴ Individuals with low vitamin A showed histopathological changes in pulmonary epithelial lignin and lung parenchyma. This result in increased risk of lung dysfunction and respiratory disease.¹⁰⁵ Vitamin E protects the integrity of respiratory epithelial barriers, against oxidative damage, induces production of interferon γ and IL-2.¹⁰⁶ Trace elements like Zn, Se, and Mg modulate enzymes, transcription factors which are needed for various biological functions including immune functions. The anti-viral properties, immune activation, complement protein activities, antioxidation, antibody production.⁹⁹ The role of micronutrients in managing long COVID sequelae is illustrated in Fig. 3.

6.2. Lactoferrin

The hyperferritinemia induced by FeRD continues for weeks or months in Long COVID patients. Managing such prolonged hyperferritinemia condition can be identified by ferritin, transferrin and lactoferrin (LF). FeRD is a sensitive, specific and useful in predicting the PASC condition.¹⁰⁷ The free iron released into the circulation produces inflammation and increases the blood viscosity. Thus, the hyperinflammation condition disrupt coagulant pathways and increase the risk of thrombosis in PASC patients.¹⁰⁸ During PASC, these redox regulators LF, heme oxygenase-1 (HO-1), erythropoietin (EPO) and hepcidin (HEP) acts as barriers and protect the host from free radical damage and hyper immune responses.⁸¹ Nutritional modification plays a significant role in managing chronic inflammatory conditions, including those seen in long COVID specific nutrients, bioactive compounds, minerals, vitamins and trace elements enhance immune function by reducing inflammation and maintaining the post-infectious inflammatory response. Immunomodulators such as N-acetylcysteine, polyphenolic compounds, probiotics and prebiotics are also tested for managing long COVID condition to address immune dysregulation, chronic inflammation, and post-viral fatigue. LF is a multifunctional glycoprotein known for its various activities such as improving anti-viral, anti-bacterial effects, and immuno booster activities.¹⁰⁹ The

iron binding role of LF is crucial for inflammatory processes, and to balance iron in blood and tissues. The function of LF in iron homeostasis disrupts the viral infection and inflammation, the iron chelating activity of LF reduces the disease severity.¹¹⁰ The anti-viral activity, immune boosting property, the influence of LF on iron homeostasis can be further evaluated for its potential mechanism as therapeutic agent for long COVID patients. The iron binding LF present in milk produces innate host defence. Oral LF supplementation prevent the oxidative damage, influence the inflammatory responses and plays a therapeutic role in clinical management of PASC.¹⁰⁷ The effect of LF on fatigue, mental symptoms, muscle strength and cognitive functions in long COVID patients was investigated by Redel and colleagues through randomized, double-blind, placebo-controlled trial for 12 weeks. Long COVID patients received 1200 mg LF daily for 6 weeks, and 6 weeks of follow up were assessed with Fatigue Assessment Scale (FAS), Hospital Anxiety and Depression Scale (HADS), Cognitive Failures Questionnaire (CFQ), and muscle strength tests. The study results showed that the score of HADS fear and depression, CFQ, and FAS were decreased but not significant with placebo. Improvement in fatigue was seen in both placebo and LF group at week 6, but not continued to show improvement in the following weeks.¹¹¹

6.3. Probiotics and prebiotics

Probiotics are able to restore gut microbiota, reduce gut microbial dysbiosis, and act as an important factor as a preventive and therapeutic strategies in combating long COVID. Though the clinical involvement of probiotics in long COVID is currently not fully described, one study indicated that probiotics could help in improving the long COVID psychological symptoms.¹¹² Dietary supplements with probiotics and prebiotics balance the gut microbiome and regulate the bidirectional gut-lung interaction.¹¹³ Probiotics and prebiotics enhance the activity of macrophages, regulate the production of short chain fatty acids, and balance T cells.¹¹⁴ Some probiotics are reported to interact with Angiotensin-Converting Enzyme 2 (ACE2) receptor or release peptides




Fig. 3. The functions of micronutrients, prebiotics and probiotics in alleviating long COVID symptoms. ATP- Adenosine triphosphate; IL-2, IL-6 – Interleukin-2, 6; TNF-α-tumour necrosis factor-alpha; ω-3 fatty acids-omega-3 fatty acids.

with high affinity for ACE2 receptors.¹¹⁵ Immunologically probiotics positively enhance natural killer cells, interferons, T and B lymphocytes, and antigen-presenting cells in the lungs.¹¹⁶ Certain probiotics, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Lactobacillus rhamnosus*, *Lactobacillus casei*, *Lactobacillus gasseri*, *Pediococcus pentosaceus*, and *Leuconostoc mesenteroides* are found to reduce the burden of COVID-19.¹¹⁶ Probiotics alleviate the long COVID respiratory issues. Another study demonstrated the link between members of Proteobacteria and long COVID symptoms. The stool samples of recovered health care workers at 3 months after discharge compared to healthy controls showed that altered gut microbiota of health care coworkers recovered from COVID-19 at 3 months after discharge. The 16sRNA sequencing revealed that health care workers had reduced bacterial diversity and significantly higher relative abundance of opportunistic pathogens. This clearly shows that gut microbiota plays an important role in the recovery from long COVID sequelae.¹¹⁷ Probiotics are being studied for improving the psychological symptoms observed in long COVID patients. The neuroinflammation in long COVID involves high cytokine levels, T-cell and natural killer cell proliferation, monocyte activation, neuronal damage, CD8⁺ T lymphocyte infiltration, and microglial activation.^{118–120} Probiotics modulate the pro-inflammatory cytokines, reduce microglial activation. In addition the byproducts short chain fatty acids (SCFA) protect the blood brain barrier integrity, control neuroinflammation, and overall contribute to the neurological health improvement. The metabolites like GABA and serotonin produced by probiotics and gut microbiota help in coordinating the brain

functions and mitigate the anxiety.¹²¹ Prebiotic components such as polyunsaturated fatty acids, resistant starch, arabino-oligosaccharides, oligosaccharides, fructans, galactomannan, lactosucrose, psyllium, lactobionic acid, and polyphenols improve gut microbiota by bolstering the growth and survival of probiotics.^{122,123} Prebiotics are found to control gastrointestinal symptoms in patients suffered by COVID infection.¹²⁴ Prebiotics regulate immune response positively by reducing the pro-inflammatory IL-6 and improving anti-inflammatory IL-10.¹²⁵

A mixture of prebiotics and probiotics SIM01 consists of beneficial strains *Bifidobacterium adolescentis*, *B. bifidum*, *B. longum* and prebiotic compounds like galacto-oligosaccharides, xylo-oligosaccharides, and resistant dextrin given to patients with COVID-19. After 6 weeks of treatment, SIM01 improved the gut microbiota most abundantly the butyrate producing bacteria in the gut. SIM01 suppressed the pathogenic bacteria *Klebsiella* which is associated with long COVID.¹²⁶ Another clinical study evaluated the effect of probiotic mixture VSL#3®, a combination of *B. breve*, *B. longum*, and *B. infantis* and *Lactobacillus acidophilus*, *L. plantarum*, *L. casei*, *L. bulgaricus*, and *Streptococcus thermophilus* on the fatigue and other symptoms in long COVID syndrome. This randomized, double blind, placebo controlled clinical study with probiotic mixture VSL#3® reduced fatigue, and significantly improved physical functioning and gastrointestinal symptoms.¹²⁷ Probiotic or bacteriotherapy are beneficial in enhancing gut microbial homeostasis, supporting host immune response to pathogens. However, there is a lack of evidences about how probiotic components help in alleviating long COVID symptoms. Still certain clinical trial evidences

are compelling that probiotic supplements during COVID infection have potential impact on the disease symptoms and disease course. The effects of probiotics in treating COVID symptoms are significant particularly in respiratory and gastrointestinal symptoms, and also showed lower risks.¹²⁸ Extensively probiotics can also be recommended for long COVID patients to prevent the follow up symptom progression. Table 2 summarizes the detailed studies using various nutrients and supplements in alleviating long COVID symptoms.^{68,81,83,92,111,129–145}

6.4. Medicinal plants, phytochemicals, and plant-based diet

Phytochemicals are of great interests in reducing viral infection risks. The bioactive component of turmeric, curcumin show strong anti-inflammatory and anti-viral activities.¹⁴⁶ A clinical study states that oral curcumin administration reduces the recovery time, needs for oxygen, mechanical ventilation, length of hospitalization, and many inflammatory markers.¹⁴⁷ Flavonoid quercetin is also found with its preventive properties, anti-inflammatory, anti-oxidant, and immuno-modulation activities.¹⁴⁸ In addition to the food practices and physical exercises, sleep is essential for proper immune function, emotional balance, muscle restoration, metabolism, and cognitive functions.¹⁴⁷ Intake of polyphenols-rich diet for 8 weeks could significantly alter gut microbiome, enhance gut repair, thereby control immune response, cytokine release.¹⁴⁹ Flavonoid-rich diet increased butyrate producing bacteria such as *Roseburia*, *Eubacterium*, *Bifidobacterium*, and *Bacteroides*.¹⁵⁰ Vitamins A, B, C, E, and K, omega-3-fatty acids, and mono-unsaturated fatty acids exhibit anti-inflammatory, immunomodulatory effects.¹⁵¹ Mediterranean diet with trace elements like iron, copper, zinc, sodium, potassium, molybdenum, magnesium, and calcium, exhibits anti-viral, anti-oxidant activity, inhibits NF- κ B signalling, and promotes IFN- α synthesis and T cell regulation.¹⁵² Anti-inflammatory diet in particular the Mediterranean diet shows promising effects. A study conducted among 305 individuals who are in Mediterranean diet found lower uric acid levels, reduced body mass index, and increased high density lipoprotein cholesterol level. These findings suggested that dietary patterns mitigated the systemic inflammation, improved metabolic health by alleviating long COVID symptoms. Thus, the dietary patterns positively influence immune responses, gut microbiome composition, metabolite production, inflammatory status. The fibre rich foods reduce oxidative stress and alleviate long COVID symptoms. Flavonoid containing foods control the inflammatory reactions and exhibit anti-vital activities as well.¹⁵³

Plant-based diet (PBD) high in vitamins, folate, fibre, and phytochemicals like carotenoids, flavonoids, and polyphenols^{96,154} enhanced immune functions, neurotransmitter release, improved sleep, reduction of pain and inflammation, and was good at mental health, which suggested that plant-based diet can have positive effect COVID consequences.¹⁵⁵ Plant-based diet includes minimally processed fruits, vegetables, grains, legumes, nuts, seeds, and herbs, excluding animal products like red meat, poultry, fish, eggs, and dairy products.¹⁵⁶ The positive effect of PBD promoted gut health and balanced microbiota and high level of beneficial microorganism.¹⁵⁷ Medicinal plants possess a vital role in fighting against fatigue caused by different factors. The minimal toxicity and easy accessibility of medicinal plants make it as a prospective one in managing post long COVID.¹⁵⁸ A RCT study using herbal combination of *Eleutherococcus*, *Rhodiola rosea* extract, and *Schisandra* extracts revealed that the herbal combination decreased the duration of post COVID-19 fatigue.¹⁵⁹ Another RCT study with essential oil blend derived from *Thymus vulgaris* L. *Citrus × aurantium* L. (Orange peel), *Syzygium aromaticum* (L.) Merr. & L.M.Perry (Clove bud), and *Boswellia sacra* Flück. (Frankincense) showed reduced fatigue scores on Multidimensional Fatigue Symptom Inventory (MFSI) among participants who breathed the essential oil blend for 14 days.¹⁶⁰ HRG80 Red Ginseng is a herbal formulation from *Panax Ginseng* that possesses greater concentration of bioavailable ginsenosides significantly, and is found to improve post-COVID fatigue.¹⁶¹ The network pharmacology

study by Zhang et al. revealed that the active components of Bu-Zhong-Yi-Qi (a traditional Chinese herbal formula) decoction has positive effects on inflammatory signalling pathways, thereby targeting crucial protein including IL-1 β , IL-6, CHRM1, OPRM1, MAPK3, and VEGFA.¹⁶² One important principal component plant called *Radix Astragali* has shown great potential in alleviating post COVID fatigue by enhancing anti-inflammatory mechanism and reducing the IL-6, IL-1 β , and TNF- α .¹⁵⁸ The Traditional Chinese medicines such as herbs and herbal blends like Bu-Zhong-Yi-Qi, Dang-Gui-Shao-Yao-San, and Qing-jin-Yi-qi granules already addressed in controlling post COVID fatigue. However most of the studies focused on fatigue lack clinical studies to confirm their effectiveness in other molecular pathways of long COVID pathophysiology.

7. Lifestyle and rehabilitation for long COVID recovery

The risk of COVID infection, disease severity, and disease related mortality created a global burden and an urge to make prominent steps, in order to change the risky situation. Changes in lifestyle and diet or nutritional interventions, including regular exercises, adequate sleep, plant-based diets, and maintaining optimal diet promote positive health outcomes during and after COVID infection.¹⁴⁷ Obese individuals are more likely to get infected with COVID and become vulnerable target for infection due to the increased expression of ACE2 receptors in adipose tissues compared to lungs, in which the adipose tissue can become a viral reservoir.¹⁶³ Another study analysed participants with obesity showed significantly higher PASC score that acts as an indicator of long COVID. And post-vaccination, obese individuals pose higher risk of prolonged COVID-19 symptoms.¹⁶⁴ Long COVID management involves differential diagnosis and comprehensive evaluation of organ damage, post-ICU effects, metabolic and endocrine disorders. As for rehabilitation, exercise-based therapy are important management elements to develop functional improvement in long COVID.¹⁶⁵ 8 weeks of aerobic exercises, resistance training/respiratory muscle training program in long COVID patients significantly reduced dyspnea, fatigue, depression and improved functional capacity.¹⁶⁶

Physical activity and exercise are the critical components in long COVID management. Tailored exercise regimens can modulate long COVID symptoms by enhancing cardiovascular health, improving mood, and reducing inflammation. The reduced physical activity during COVID infection due to social distancing and quarantine, reduces the ability of organ systems to fight back the viral infection, causing risks to immune, respiratory, cardiac, musculoskeletal, and brain. In a work by Woods and team, they highlighted how COVID viral infection damaged physiological systems of human, physical inactivity associated viral outbreaks to the body, and promising strategies to recover from the potential damage.¹⁶⁷ Physical inactivity is associated with many serious effects like reduced insulin sensitivity, mitochondrial function, and lipoprotein metabolism.¹⁶⁸ Long-term bed rest and prolonged physical inactivity disrupt the mitochondrial homeostasis, reduce protein synthesis, and increase protein degradation. Disturbance in the mitochondrial homeostasis causes systemic inflammation, reactive oxygen species generation, production of pro-inflammatory cytokines and functional decline.¹⁶⁹ The higher physical fitness improves immune responses to vaccination, reduces chronic low-grade inflammation and improves various immune markers in several diseases.¹⁷⁰ Regular physical activity modulates inflammatory pathways, reduces fatigue and cognitive dysfunction, and attenuates PASC. Physical fitness affects the SARS-CoV-2 infections and its severity. But during the COVID-19 pandemic, physical activity and exercise had both positive and negative impact on individual health. It was found that infection was increased and caused cardiac damage due to inflammatory reaction in the muscle cells and coronary.^{171,172} Regular physical activity also had positive effects on cardiorespiratory fitness and longevity. Regular physical activities have anti-depressive and neuroprotective effects. Exercises have positive effects on the brain and induce endorphin release

Table 2
Various studies on nutritional interventions in long COVID.

S. No	Nutrients/supplements	Study type	Study group	Key findings	References
Intervention with fermented products/probiotics/prebiotics/synbiotics					
1	Synbiotic preparation (SIM01) mixture of Prebiotics- galacto-oligosaccharides, xylo-oligosaccharides, resistant dextrin; Probiotics- <i>B. adolescentis</i> , <i>B. bifidum</i> ; <i>B. longum</i> . Placebo – low doses of vitamin C (1 mg sachets) Twice daily for 6 months	Randomized, double blind, placebo-controlled trial	SIM01 <i>n</i> = 232 Placebo <i>n</i> = 231	Reduced fatigue, memory loss, concentration, gastrointestinal discomforts and improved physical functioning	129
2.	Bacteriotherapy formulation SLAB51 (Sivomixx800®, Ormendes, Switzerland) contained <i>S. thermophilus</i> DSM 32245®, <i>B. lactis</i> DSM 32246®, <i>B. lactis</i> DSM 32247®, <i>L. acidophilus</i> DSM 32241®, <i>L. helveticus</i> DSM 32242®, <i>L. paracasei</i> DSM 32243®, <i>L. plantarum</i> DSM 32244®, and <i>L. brevis</i> DSM 27961®. The supplementation received thrice daily throughout their stay.	Retrospective Observational study	<i>n</i> = 58 patients hospitalized for COVID-19 and discharged to home care. <i>n</i> = 24 patients received standard treatment + oral bacteriotherapy; <i>n</i> = 34 patients received conventional standard treatment.	Patients underwent oral bacteriotherapy showed significant reduction in chronic fatigue and higher levels of lactate, arginine and asparagine in serum.	130
3	Blend of 5 species of probiotic lactobacillus: <i>L. plantarum</i> (Lp90); <i>L. rhamnosus</i> (LRa05); <i>L. bulgaricus</i> (LB42); <i>L. lactis</i> (La61); <i>L. paracasei</i> (LC86) and prebiotic inulin derived from chicory.	Clinical trial study	<i>n</i> = 126; had one or more symptoms related to their COVID infection at the time of trial entry	Probiotic treatment improved the gut health. Subject well-being and GI symptoms by reducing fatigue, cough and gut inflammation.	131
4	14 g of Fermented fruit syrup from Noni (<i>Morinda citrifolia</i> Linn) as BioRex Noni in the morning after breakfast and 14 g of fermented fruit syrup from papaya (<i>Carica papaya</i> Linn.) as BioRex papaya after dinner for 20 days. Placebo group received 5% honey diluted by tap water following the same protocol.	Randomized, placebo-controlled clinical laboratory study	<i>n</i> = 188 adults, 38–69 years of age who suffered moderate or severe COVID-19 infection (<i>n</i> = 157 delta variant virus; <i>n</i> = 31 omicron variant virus).	Il-6 and Il-8 and nitri oxide metabolites reduced significantly. The polymorphonuclear leukocyte capacity to phagocyte anti-oxidant activity and ATP content were remarkably increased. Oral-pharyngeal microbiota remains unchanged.	132
5	Oral food supplement containing 4% echinacoside from <i>Echinacea angustifolia</i> , Rosehip, vitamin C, Lyophilized royal jelly and zinc. 2 capsules/day for 2 months	Randomized, double blind, placebo-controlled trial	<i>n</i> = 33 long COVID patients with mean age of (47.6 ± 16.05) years	Inflammatory parameters like neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ration and C-reactive protein were significantly reduced in oral food supplement period compared to placebo period. Fatigue reduced and quality of life improved	133
Intervention with different types of vitamins					
6	240 µg K2 (pure MK-7 form) and 2 000 IU vitamin D3 or standard of care for 6 weeks.	Single site RCT	<i>n</i> = 151 participants; 46 years median age. <i>n</i> = 98 received VitK2/D3; <i>n</i> = 53 received standard of care. Adults experienced ≥ 2 moderate long COVID symptoms for atleast 3 months after COVID-19 infection were selected for the study.	The treatment group showed improved 25(OH) D levels. Participants received Vit K2/D3 showed a 7.1% reduction in long COVID symptoms compared to control group. Vit K2/D3 improved the RECOVER long COVID index, number of symptoms, gut and inflammatory markers.	68
7	Intervention group received 1 300 mg magnesium chloride+4 000 IU vitamin D; control group received 4 000 IU vitamin D for 4 months.	Open-label, randomized, controlled clinical trial	<i>n</i> = 60 long COVID patients diagnosed with hypomagnesemia, vitamin D deficiency and mild to moderate depression. <i>n</i> = 30 intervention; <i>n</i> = 30 control group.	Mild to moderate depression was studied using Beck Depression Inventory (BDI). BDI scores were significantly reduced in intervention group and control group. Combined oral supplementation of magnesium and vitamin D is effective in patients with hypomagnesemia and vitamin D deficiency.	83
8	Two broad categories of interventions included in the study, one is focused on nutrients such as multiple B group vitamins, vitamin C, vitamin D, acetyl-l-cartinine and mineral supplements, other one is multidisciplinary rehabilitation programs.	Systemic scoping review	5 pilot studies. <i>n</i> = 2 pilot studies focused on nutrients; <i>n</i> = 3 pilot studies focused on multidisciplinary rehabilitation programs	The nutritional rehabilitation is important for recovery from inflammation, malnutrition and sarcopenia	92
9	Vitamin D	Phase 3 open label RCT	<i>n</i> = 6 200 people aged ≥ 16 years <i>n</i> = 3 100 people assigned to receive no offer of postal Vit D test ot Vit D supplements; <i>n</i> = 1 550 assigned to offer postal Vit D test with supply of 800 IU Vit D/day; <i>n</i> = 1 550	Vitamin D supplementation was found not associated with reduction in risk of COVID-19.	134

(continued on next page)

Table 2 (continued)

S. No	Nutrients/supplements	Study type	Study group	Key findings	References
10	Studies with essential vitamins including Vit C, Vit D, Vit E, Vit k, Vit B1 (thiamine), Vit B2 (riboflavin), Vit B3 (niacin), Vit B5 (pantothenic acid), Vit B6 (pyridoxine), Vit B7 (biotin), Vit B9 (folic acid), Vit B12 (cyanocobalamin)	Systemic review according to Cochrane Handbook for Systematic Reviews and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement	assigned to offer postal Vit D test with supply of 3 200 IU Vit D/day RCTs articles published in English or Italian with direct effects including vitamin administration. Placebo/SOC in relation to prevention and management of COVID-19 and Long COVID in people of any age.	The effects of vitamin D in preventing COVID-19 and long COVID were contrasting, No conclusion can be drawn on the effect of multivitamins, Vit A and Vit B in COVID management. Vit D showed improvement in long term complications of COVID-19	135
11	60 000 IU of Vitamin D weekly for 8 weeks. Placebo group received starch powder capsule once weekly for 8 weeks.	Randomized, double-blind, placebo-controlled trial	$n = 80$ patients, 18–60 years with post-COVID fatigue or neuropsychiatric symptoms; $n = 40$ post COVID patients; $n = 40$ placebo.	Vitamin D group patients showed significant improvements in CFQ, DASS-anxiety and ACE. No significant changes were found PQSI, DASS depression, TMT, IL-6 or CRP levels. Vit D supplementation v = benefitted the post COVID patients by reducing fatigue, anxiety and improving cognitive symptoms with very low side effects.	136
12	Single oral dose of 200 000 IU Vitamin D3 diluted in 10 ml peanut oil solution. Placebo group received only 10 ml peanut oil solution.	Multicentre, double-blind, placebo-controlled, randomized clinical trial	$n = 144$ patients with mean age 54.3 years; $n = 71$ vitamin D3 group; $n = 71$ placebo group	No significant differences were observed between Vit D3 and placebo group for fever, fatigue, myalgia, joint pain, runny nose, nasal congestion, hypertension, diabetes, cardiovascular disease, Quality of life upto 1 year of follow up.	137
13	Oral tablets of 600 mg Vitamin B1 daily for 8 weeks along with supportive therapy (vitamin C, famotidine, zinc). Control group received only the supportive therapy.	An open-label, randomized, controlled trial	$n = 66$ with mean age 49.35 years, recovered COVID-19 patients experiencing post-COVID syndrome.	After 5 weeks of vitamin B3 supplementation, treatment group showed significantly shortened symptoms like myalgia, anosmia, ageusia, fatigue and sleep disturbances compared to control group. The recovery rate in vitamin B3 group was twice than that of the control group.	138
14	Patients received 14 days oral vitamin A 25 000 IU per day and aerosolised diffuser olfactory training for combination treatment; olfactory training alone for standard care; observation for control for 4 weeks.	Pilot trial study	$n = 24$ long COVID patients with persistent olfactory dysfunction, randomly assigned for combination treatment $n = 10$; standard care $n = 9$; control $n = 5$.	Scores of olfactory function assessed by butanol threshold tests, smell identification scores and olfactory cortical network analysed by resting state fMRI showed significantly higher scores in combination treatment group compared to other groups.	139
Intervention with nutraceuticals/amino acids/other proteins					
15	Amino-Ther Pro (10 amino acids + vitamins B1 and B6 + organic acids), 2 servings/day for 8 weeks	A pilot observational case-control study	$n = 66$ COVID survivors with mean age (61.0 ± 11.8) years; $n = 33$ intervention; $n = 33$ control group.	Skeletal muscle index, physical performance was measured by using Handgrip dynamometry, 1-min chair-stand, 6-min walk test, and quality of life was assessed by EuroQol visual analogue scale. Nutritional supplementation imparted a positive effect on nutritional status, functional recovery and quality of life.	81
16	1 200 mg Lactoferrin daily for 6 weeks.	Randomized, double-blind, placebo-controlled trial	Long COVID patients aged 18–70 years, within 12 months after SARS-CoV-2 infection.	Lactoferrin and placebo group showed significant reduction in fatigue in week 0 and week 6 as measure by Fatigue Assessment Scale. No efficacy of lactoferrin were found in outcomes of anxiety, depression and cognitive failure.	111
17	Nutraceutical formulation of active ingredients containing β -caryophyllene (one serving - 40 mg), Pregnenolone (40 mg), Dehydroepiandrosterone (30 mg), Bromelain (416 mg), St. John's Wort extract (150 mg), Boswellia Serrata gum/resin extract (100 mg), Quercetin (40 mg), Zinc picolinate (12 mg) and Vitamin D (1 000 IU)	One arm open label clinical trial	$n = 51$ COVID long hauler patients. Ingredients one serving twice a day with food for 4 weeks.	The severity score for symptoms like fatigue, physical weakness, palpitations, brain fog, shortness of breath, gastro intestinal disorders, loss of smell, taste senses, anxiety, joint pain, rashes, cough and insomnia improved after 2 weeks and even more improved after 4 weeks.	140
18	1.66 g L-Arginine +500 mg Vitamin C combination (Bioarginina® C, Farmaceutici Damor, Naples, Italy) or placebo supplementation for 28 days	RCT	Trial participants aged 20–60 years with previous confirmed SARS-CoV2 infection, and negative COVID-19 test atleast 4 weeks prior to enrollment and long covid diagnosis	Participants showed improved L-arginine concentrations and L-arginine/ADMA increased compared to placebo participants. A marker of	141

(continued on next page)

Table 2 (continued)

S. No	Nutrients/supplements	Study type	Study group	Key findings	References
19	22 g collagen peptides supplementation or an isocaloric carbohydrate diet twice daily for 6 weeks.	Two arm randomized double blind-controlled intervention	as per national and international criteria $n = 59$ adults post ICU patients, ≥ 18 years.	NO biosynthetic capacity increased compared to placebo. Patients showed improved as well as higher scores of physical functioning	142
20	PIRV-F20® a combination of lactoferrin, lysozyme, lactobacillus, resveratrol, vitamins and oligo elements for 6 weeks.	A single-center retrospective study	$n = 44$ long COVID patients with mean age (49.1 ± 18.1) years with atleast one persistent long COVID syndrome.	Intervention group showed significant improvement in 6-min walking test and exercise capacity compared to control. In muscular strength, echocardiographic parameters and perception of symptoms no differences were found between control and intervention groups	143
21	Apportal® one sachet daily for 28 days. It contains 19 nutrients including Vitamin B group, minerals in Sucrosomial® forms like iron, zinc, magnesium and selenium, amino acids arginine and carnitine, plant extracts Panax ginseng and <i>Eleutherococcus senticosus</i> .	Observational study	$n = 201$ participants, (48.11 ± 13.16) years age, who had contracted COVID-19 and overcame the acute phase of infection at least 3 days without fever and other symptoms except ageusia and anosmia	Quality of life and health status were assessed through EuroQoL-5D questionnaire and mental fatigue was measured by modified chalder questionnaire. Significant improvement in all indexes was observed after 14 and 28 days of intervention. Apportal® reduced chronic fatigue, improved quality of life and health status.	144
22	Apportal® one sachet daily for 28 days. It contains 19 nutrients including Vitamin B group, minerals in Sucrosomial® forms like iron, zinc, magnesium and selenium, amino acids arginine and carnitine, plant extracts Panax ginseng and <i>Eleutherococcus senticosus</i> .	Observational exploratory study	$n = 30$ participants with (56.14 ± 13.9) years of age, still suffering long COVID sequelae and admitted to post COVID outpatient service.	Muscle strength and physical performance were evaluated by hand held hydraulic dynamometer and 1-min sit-to-stand test respectively. Body composition and blood biochemistry were also accessed. Hand grip strength and physical performance improved, ferritin levels reduced	145

IU- international unit; ICU- intensive care unit; RCTs-randomized clinical trials; SOC- standard of care. CFQ- Chalder Fatigue scale; DASS- Depression, Anxiety and Stress Scale; PSQI-Pittsburgh Sleep Quality Index; ACE-Addenbrooke's Cognitive Examination; ATP-adenosine tri phosphate.

particularly after running. Regular exercise also attenuated symptoms of quarantine-induced depression.^{167,173} Many studies focused on the effect of physical activities in COVID infection and post infection are listed in Table 3.^{174–183}

8. Limitations and future directions

Treating long COVID poses numerous challenges like lack of consensus on its definition and diagnosis, limited understanding of pathophysiology including immune dysregulation, heterogeneity of symptoms, misattributions, and stigma as well. Addressing multiple symptoms in a single individual and treating it separately is challenging. The weak evidence based on long COVID treatments is due to the limitation in designing the clinical trials for long COVID. Many symptoms differentiated among each patient, appearance and warning of symptoms, lack of streamlined methodological formats, sample sizes, follow up periods.¹⁸⁴ Common attributes involving synergistic effects of diet, physical activities and rehabilitation can be supportive in reducing the long COVID symptoms. The sequelae of damaged tissues, viral particles persistence in organs, immune dysregulation, elevated auto immunity, chronic inflammation, tissue hypoxia, coagulopathy and endothelial damage are complicated, but synergistic effects of various dietary components can be helpful. The nutritional strategies face multifaceted challenges. One common nutritional approach is not feasible and applicable to all patients; hence an individualized dietary intervention is necessary.¹⁸⁵ The malnutritional condition further delays the recovery time and increases the hospitalization period. According to the nutritional supplement protocol of non-critical COVID patients by Caccialanza and team, their observation states that patients during hospitalization affected by severe inflammatory status and anorexia, which leads to reduced intake of food. In their protocol, initially the patients supplemented with oral food supplements, if patients could not

be able to tolerate the intake of oral food supplements, they are switched to intravenous supplementation of nutrition including whey proteins, vitamins and minerals to meet the recommended dietary allowance (RDA) required for their health.¹⁸⁶

9. Conclusion

Nutritional interventions offer an integrative approach that may address underlying malnutrition, micronutrient deficiencies, chronic inflammation and metabolic dysregulation observed in patients with long COVID conditions. Executing a prompt and accurate nutritional care is still a great challenge owing to the differences in each patient's need and circumstances. Although few trials combine dietary supplements with nutraceuticals and functional foods in long COVID patients, the details of dosage, route of administration, duration of intervention, ratio of combining the supplements still remains a big challenge. Maintaining healthy hygienic life style, body weight control and healthy food habits were recognized as important factors in controlling the severity of long COVID symptoms. The intervention with functional foods, nutraceutical and dietary supplements are essential to enhance the immune function, to control the oxidative stress, and inflammation. Various studies involving clinical trials explaining the importance of nutritional therapy in lowering the adverse long-term effects of COVID infection. Still identifying the individual patient specific need for nutritional supplements, the limited required quantity and duration of nutrient interventions. Possible mechanism of action of the supplements and nutrients to expect the positive and negative effects of the interventions.

CRedit authorship contribution statement

Subramanian Thangaleela: Writing – review & editing,

Table 3
Role of exercises and physical activities in alleviating long COVID symptoms.

S. No	Type of study	Intervention	Study subjects	Key findings	References
1	Systemic review and meta-analysis	Exercises such as aerobic exercise, multimodal exercise, breathing exercise, and Taichi	9 studies involving 672 individuals	Exercises significantly improved long COVID fatigue, no significant effect was found in long COVID anxiety, depression and cognitive impairment. Multimodal exercises had benefits on long COVID fatigue, dyspnea and depression. Passive control group with intervention frequency ≤ 4 times/week showed positive effects on long COVID symptoms.	174
2	Cross-sectional Retrospective study	Regular exercises	309 teacher-training college students	Students who have daily physical activity practices had fewer symptoms. Sustained physical activity reduced burden of symptoms	175
3	Systemic review and meta-analysis	Physical exercise- based rehabilitation	23 studies involving 1579 individuals who had COVID-19.	Physical exercise-based rehabilitation reduced COVID-19 symptoms including dyspnea, fatigue, depression and improved quality of life	176
4	Comparative study	Exercise rehabilitation 4 weeks, 3 sessions/week	38 long COVID patients received exercise rehabilitation, 38 coronary artery disease patients, 38 fibromyalgia patients.	Cardiorespiratory and muscular parameters were improved after exercise rehabilitation in all three groups.	177
5	RCT	Exercise focused intervention for 3 months	62 patients with post COVID syndrome	Fatigue was significantly decreased.	178
6	RCT	Online therapeutic exercise for 8 weeks	70 previously hospitalized COVID-19 survivors.	Patients in intervention group experienced improvements in hand grip strength, balance and frailty.	179
7	Systematic review of RCTs	Exercise interventions	8 studies included Sample sizes ranged from 39 to 119 with mean 56.	Exercise interventions showed short-term improvements in symptoms dyspnoea, fatigue, physical function and quality of life among people with long COVID	180
8	A systematic review and non-linear dose–response meta-analysis	Regular physical activity	16 studies were included.	Regular physical activity lowered COVID-19 outcomes, reduced the risk of severe COVID-19.	181
9	Retrospective study	8 weeks of resistance training	Post COVID elders tested positive for COVID 3–12 months before	Moderate intensity resistance training for 8 weeks did not sufficiently improved body mass and body composition.	182
10	Two-arm RCT	Personalized resistance exercise intervention and usual care for 12 weeks	Individuals from a community and post-hospitalized with long COVID	Resistance exercise improved exercise capacity, health, quality of life, grip strength and reduced anxiety and depression.	183

RCT-randomized control trial.

Investigation. **Chin-Kun Wang:** Writing – review & editing, Supervision, Conceptualization, Writing – review & editing, Methodology, Conceptualization.

Funding

None to declare.

Declaration of competing interest

Chin-Kun Wang is an Editorial Board Member for Sports Medicine and Health Science and was not involved in the editorial review or the decision to publish this article. The authors of this manuscript have no conflict of interest.

Acknowledgement

The authors gratefully acknowledge Chung Shan Medical University, Taichung city, Taiwan China, for its support.

References

- Liu X, Huuskonen S, Laitinen T, et al. SARS-CoV-2–host proteome interactions for antiviral drug discovery. *Mol Syst Biol.* 2021;17(11):e10396. <https://doi.org/10.15252/msb.202110396>.
- Banerjee AK, Blanco MR, Bruce EA, et al. SARS-COV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. *Cell.* 2020;183(5):1325–1339.e21. <https://doi.org/10.1016/j.cell.2020.10.004>.
- Wang T, Cao Y, Zhang H, et al. COVID-19 metabolism: mechanisms and therapeutic targets. *MedComm.* 2022;3(3):e157. <https://doi.org/10.1002/mco2.157>.
- Naidu AS, Shahidi F, Wang CK, et al. SARS-COV-2-induced Host Metabolic Reprogram (HMR): nutritional interventions for global management of COVID-19 and post-acute sequelae of COVID-19 (PASC). *J Food Bioact.* 2022;18:1–42. <https://doi.org/10.31665/jfb.2022.18306>.
- Hallek M, Adorjan K, Behrends U, et al. Post-COVID syndrome. *Dtsch Arztebl Int.* 2023;120(4):48–55. <https://doi.org/10.3238/arztebl.m2022.0409>.
- Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *eClinicalMedicine.* 2021;38:101019. <https://doi.org/10.1016/j.eclinm.2021.101019>.
- Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature.* 2020;(583):459–468. <https://doi.org/10.1038/s41586-020-2286-9>.
- Naidu AS, Wang CK, Rao P, et al. Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID. *Npj Sci Food.* 2024;8(1):19. <https://doi.org/10.1038/s41538-024-00261-2>.
- Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med.* 2022;28(3):583–590. <https://doi.org/10.1038/s41591-022-01689-3>.
- Bornstein SR, Cozma D, Kamel M, et al. Long-COVID, metabolic and endocrine disease. *Horm Metab Res.* 2022;54(8):562–566. <https://doi.org/10.1055/a-1878-9307>.
- Kedor C, Freitag H, Meyer-Arndt L, et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. *Nat Commun.* 2022;13(1):5104. <https://doi.org/10.1038/s41467-022-32507-6>.
- Larsen NW, Stiles LE, Shaik R, et al. Characterization of autonomic symptom burden in long COVID: a global survey of 2,314 adults. *Front Neurol.* 2022;13:1012668. <https://doi.org/10.3389/fneur.2022.1012668>.
- Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep.* 2021;11:16144. <https://doi.org/10.1038/s41598-021-95565-8>.
- Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. *Infect Dis (Lond).* 2021;53(10):737–754. <https://doi.org/10.1080/23744235.2021.1924397>.
- Carolin A, Frazer D, Yan K, et al. The effects of iron deficient and high iron diets on SARS-CoV-2 lung infection and disease. *Front Microbiol.* 2024;15:1441495. <https://doi.org/10.3389/fmicb.2024.1441495>.
- Baig AM. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. *ACS Chem Neurosci.* 2020;11(24):4017–4020. <https://doi.org/10.1021/acscchemneuro.0c00725>.

17. Shang C, Liu Z, Zhu Y, et al. SARS-CoV-2 causes mitochondrial dysfunction and mitophagy impairment. *Front Microbiol.* 2022;12:780768. <https://doi.org/10.3389/fmicb.2021.780768>.
18. Romão PR, Teixeira PC, Schipper L, et al. Viral load is associated with mitochondrial dysfunction and altered monocyte phenotype in acute severe SARS-CoV-2 infection. *Int Immunopharmacol.* 2022;108:108697. <https://doi.org/10.1016/j.intimp.2022.108697>.
19. Singh KK, Chaubey G, Chen JY, Suravajhala P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. *AJP Cell Physiol.* 2020;319(2):C258–C267. <https://doi.org/10.1152/ajpcell.00224.2020>.
20. Saleh J, Peyssonnaud C, Singh KK, Edeas M. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. *Mitochondrion.* 2020;54:1–7. <https://doi.org/10.1016/j.mito.2020.06.008>.
21. Moolamalla STR, Balasubramanian R, Chauhan R, et al. Host metabolic reprogramming in response to SARS-CoV-2 infection: a systems biology approach. *Microb Pathog.* 2021;158:105114. <https://doi.org/10.1016/j.micpath.2021.105114>.
22. Shen T, Wang T. Metabolic reprogramming in COVID-19. *Int J Mol Sci.* 2021;22(21):11475. <https://doi.org/10.3390/ijms22111475>.
23. Montalvan V, Lee J, Bueso T, et al. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. *Clin Neurol Neurosurg.* 2020;194:105921. <https://doi.org/10.1016/j.clineuro.2020.105921>.
24. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J.* 2020;41(32):3038–3044. <https://doi.org/10.1093/eurheartj/ehaa623>.
25. Stefano GB, Ptacek R, Ptackova H, et al. Selective neuronal mitochondrial targeting in SARS-CoV-2 infection affects cognitive processes to induce 'brain fog' and results in behavioral changes that favor viral survival. *Med Sci Monit.* 2021;27:e930886. <https://doi.org/10.12659/msm.930886>.
26. Akbarialiabad H, Taghbir MH, Abdollahi A, et al. Long COVID, a comprehensive systematic scoping review. *Infection.* 2021;49(6):1163–1186. <https://doi.org/10.1007/s15010-021-01666-x>.
27. Mehandru S, Merad M. Pathological sequelae of long-haul COVID. *Nat Immunol.* 2022;23(2):194–202. <https://doi.org/10.1038/s41590-021-01104-y>.
28. Tejera D, Mercan D, Sanchez-Caro JM, et al. Systemic inflammation impairs microglial A β clearance through NLRP3 inflammasome. *EMBO J.* 2019;38(17):e101064. <https://doi.org/10.15252/embj.2018101064>.
29. Holdaway A. Nutritional management of patients during and after COVID-19 illness. *Br J Community Nurs.* 2020;25(Sup8):S6–S10. <https://doi.org/10.12968/bjcn.2020.25.sup8.s6>.
30. Antwi J, Appiah B, Oluwakuse B, Abu BAZ. The nutrition-COVID-19 interplay: a review. *Curr Nutr Rep.* 2021;10(4):364–374. <https://doi.org/10.1007/s13668-021-00380-2>.
31. Junaid K, Ejaz H, Abdalla AE, et al. Effective immune functions of micronutrients against SARS-CoV-2. *Nutrients.* 2020;12(10):2992. <https://doi.org/10.3390/nu12102992>.
32. Lechuga GC, Morel CM, De-Simone SG. Hematological alterations associated with long COVID-19. *Front Physiol.* 2023;14:1203472. <https://doi.org/10.3389/fphys.2023.1203472>.
33. Lehmann A, Prosch H, Zehetmayer S, et al. Impact of persistent D-dimer elevation following recovery from COVID-19. *PLoS One.* 2021;16(10):e0258351. <https://doi.org/10.1371/journal.pone.0258351>.
34. Sonnweber T, Grubwieser P, Sahanic S, et al. The Impact of iron dyshomeostasis and anaemia on long-term pulmonary recovery and persisting symptom burden after COVID-19: a prospective observational cohort study. *Metabolites.* 2022;12(6):546. <https://doi.org/10.3390/metabo12060546>.
35. Klein J, Wood J, Jaycox JR, et al. Distinguishing features of long COVID identified through immune profiling. *Nature.* 2023;623(7985):139–148. <https://doi.org/10.1038/s41586-023-06651-y>.
36. Mendelson M, Nel J, Blumberg L, et al. Long-COVID: an evolving problem with an extensive impact. *S Afr Med J.* 2020;111(1):10–12. <https://doi.org/10.7196/SAMJ.2020.v111i1.15433>.
37. Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. *JAMA.* 2020;324(17):1723–1724. <https://doi.org/10.1001/jama.2020.19719>.
38. Paneroni M, Simonelli C, Saleri M, et al. Muscle strength and physical performance in patients without previous disabilities recovering from COVID-19 pneumonia. *Am J Phys Med Rehabil.* 2021;100(2):105–109. <https://doi.org/10.1097/PHM.0000000000001641>.
39. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol.* 2020;34(5):e212–e213. <https://doi.org/10.1111/jdv.16387>.
40. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect.* 2021;27(1):89–95. <https://doi.org/10.1016/j.cmi.2020.09.023>.
41. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. *N Engl J Med.* 2020;382(23):2268–2270. <https://doi.org/10.1056/NEJMc2008597>.
42. Guedj E, Campion JY, Dudouet P, et al. ¹⁸F-FDG brain PET hypometabolism in patients with long COVID. *Eur J Nucl Med Mol Imag.* 2021;48(9):2823–2833. <https://doi.org/10.1007/s00259-021-05215-4>.
43. Harris A, Creecy A, Awosanya OD, et al. SARS-CoV-2 and its multifaceted impact on bone health: mechanisms and clinical evidence. *Curr Osteoporos Rep.* 2024;22(1):135–145. <https://doi.org/10.1007/s11914-023-00843-1>.
44. Obitsu S, Ahmed N, Nishitsuji H, et al. Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. *Arch Virol.* 2009;154(9):1457–1464. <https://doi.org/10.1007/s00705-009-0472-z>.
45. Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. *Cell Discov.* 2020;6:31. <https://doi.org/10.1038/s41421-020-0168-9>.
46. Nasiri K, Mohammadzadehsaliani S, Kheradjo H, et al. Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects. *Cell Commun Signal.* 2023;21(1):103. <https://doi.org/10.1186/s12964-023-01122-3>.
47. Kronstein-Wiedemann R, Stadtmüller M, Traikov S, et al. SARS-CoV-2 infects Red Blood Cell progenitors and dysregulates hemoglobin and iron metabolism. *Stem Cell Rev Rep.* 2022;18(5):1809–1821. <https://doi.org/10.1007/s12015-021-10322-8>.
48. León-Moreno LC, Reza-Zaldívar EE, Hernández-Sapiéns MA, et al. Mesenchymal Stem Cell-based therapies in the post-acute neurological COVID Syndrome: current landscape and opportunities. *Biomolecules.* 2023;14(1):8. <https://doi.org/10.3390/biom14010008>.
49. Zeylabi F, Nameh Goshay Fard N, Parsi A, Pezeshki SMS. Bone marrow alterations in COVID-19 infection: the root of hematological problems. *Curr Res Transl Med.* 2023;71(3):103407. <https://doi.org/10.1016/j.retram.2023.103407>.
50. Zioupos P, Currey JD, Hamer AJ. The role of collagen in the declining mechanical properties of aging human cortical bone. *J Biomed Mater Res.* 1999;45(2):108–116. [https://doi.org/10.1002/\(sici\)1097-4636\(199905\)45:2<108::aid-jbm5>3.0.co;2-a](https://doi.org/10.1002/(sici)1097-4636(199905)45:2<108::aid-jbm5>3.0.co;2-a).
51. Elahi S. Hematopoietic responses to SARS-CoV-2 infection. *Cell Mol Life Sci.* 2022;79(3):187. <https://doi.org/10.1007/s00188-022-04220-6>.
52. Shastri T, Randhawa N, Aly R, Ghouse M. Bone marrow suppression secondary to the COVID-19 booster vaccine: a case report. *J Blood Med.* 2022;13:69–74. <https://doi.org/10.2147/JBM.S350290>.
53. Toom S, Wolf B, Avula A, Peeke S, Becker K. Familial thrombocytopenia flare-up following the first dose of mRNA-1273 Covid-19 vaccine. *Am J Hematol.* 2021;96(5):E134–E135. <https://doi.org/10.1002/ajh.26128>.
54. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2⁺ Mesenchymal Stem Cells improves the outcome of patients with COVID-19 pneumonia. *Aging Dis.* 2020;11(2):216–228. <https://doi.org/10.14336/AD.2020.0228>.
55. Thomas C, Faghy MA, Chidley C, et al. Blood biomarkers of long COVID: a systematic review. *Mol Diagn Ther.* 2024;28(5):537–574. <https://doi.org/10.1007/s40291-024-00731-z>.
56. Lai YJ, Liu SH, Manachevakul S, et al. Biomarkers in long COVID-19: a systematic review. *Front Med.* 2023;10:1085988. <https://doi.org/10.3389/fmed.2023.1085988>.
57. Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurol.* 2022;21(1):66–77. [https://doi.org/10.1016/S1474-4422\(21\)00361-6](https://doi.org/10.1016/S1474-4422(21)00361-6).
58. Bäckström D, Linder J, Jakobson Mo S, et al. NFL as a biomarker for neurodegeneration and survival in Parkinson disease. *Neurology.* 2020;95(7):e827–e838. <https://doi.org/10.1212/WNL.00000000000010084>.
59. Danielle RCS, Débora DM, Alessandra NLP, et al. Correlating COVID-19 severity with biomarker profiles and patient prognosis. *Sci Rep.* 2024;14(1):22353. <https://doi.org/10.1038/s41598-024-71951-w>.
60. Bellone S, Siegel ER, Scheim DE, Santin AD. Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with post-acute-COVID-sequela (PASC)/long COVID. *Gynecol Oncol Rep.* 2024;51:101324. <https://doi.org/10.1016/j.gore.2024.101324>.
61. Fogarty H, Ward SE, Townsend L, et al. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. *J Thromb Haemostasis.* 2022;20(10):2429–2438. <https://doi.org/10.1111/jth.15830>.
62. DeKosky ST, Kochanek PM, Valadka AB, et al. Blood biomarkers for detection of brain injury in COVID-19 patients. *J Neurotrauma.* 2021;38(1):1–43. <https://doi.org/10.1089/neu.2020.7332>.
63. Frontera JA, Boutajangout A, Masurkar AV, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. *Alzheimer's Dement.* 2022;18(5):899–910. <https://doi.org/10.1002/alz.12556>.
64. Peluso MJ, Sans HM, Forman CA, et al. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. *Neurol Neuroimmunol Neuroinflamm.* 2022;9(5):e200003. <https://doi.org/10.1212/NXI.0000000000200003>.
65. Magdy R, Eid RA, Fathy W, et al. Characteristics and risk factors of persistent neuropathic pain in recovered COVID-19 patients. *Pain Med.* 2021;23(4):774–781. <https://doi.org/10.1093/pm/pnab341>.
66. Mohammadi A, Balan I, Yadav S, et al. Post-COVID-19 pulmonary fibrosis. *Cureus.* 2022;14(3):e22770. <https://doi.org/10.7759/cureus.22770>.
67. Mouchati C, Durieux JC, Zisis SN, et al. Increase in gut permeability and oxidized LDL is associated with post-acute sequelae of SARS-CoV-2. *Front Immunol.* 2023;14:1182544. <https://doi.org/10.3389/fimmu.2023.1182544>.
68. Atieh O, Daher J, Durieux JC, et al. Vitamins K2 and D3 improve long COVID, fungal translocation, and inflammation: randomized controlled trial. *Nutrients.* 2025;17(2):304. <https://doi.org/10.3390/nu17020304>.
69. Giron LB, Peluso MJ, Ding J, et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF- κ B signaling. *JCI Insight.* 2022;7(18):e164813. <https://doi.org/10.1172/jci.insight.164813>.
70. Al-Khrasani M, Essmat N, Boldizsár Jr I, et al. Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? *Biomed Pharmacother.* 2025;189:118346. <https://doi.org/10.1016/j.biopha.2025.118346>.

71. Bigman G, Rusu ME, Shelawala N, et al. A Comprehensive scoping review on diet and nutrition in relation to long COVID-19 symptoms and recovery. *Nutrients*. 2025;17(11):1802. <https://doi.org/10.3390/nu17111802>.
72. Vaziri-Harami R, Delkash P. Can L-carnitine reduce post-COVID-19 fatigue? *Ann Med Surg*. 2022;73:103145. <https://doi.org/10.1016/j.amsu.2021.103145>.
73. Rostamzadeh F, Najafipour H, Yazdani R, et al. Changes in serum levels of apelin and nitric oxide in hospitalized patients with COVID-19: association with hypertension, diabetes, obesity, and severity of disease. *Eur J Med Res*. 2022;27:243. <https://doi.org/10.1186/s40001-022-00852-3>.
74. Yang CP, Chang CM, Yang CC, et al. Long COVID and long chain fatty acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. *Brain Behav Immun*. 2022;103:19–27. <https://doi.org/10.1016/j.bbi.2022.04.001>.
75. Marzetti E, Coelho-Júnior HJ, Calvani R, et al. Mitochondria-derived vesicles and inflammatory profiles of adults with long covid supplemented with red beetroot juice: secondary analysis of a randomized controlled trial. *Int J Mol Sci*. 2025;26(3):1224. <https://doi.org/10.3390/ijms26031224>.
76. Koh Y, Ho C, Pan M. The role of mitochondria in phytochemically mediated amelioration. *J Agric Food Chem*. 2023;71(18):6775–6788. <https://doi.org/10.1021/acs.jafc.2c08921>.
77. Girelli D, Marchi G, Busti F, Vianello A. Iron metabolism in infections: focus on COVID-19. *Semin. Hematol*. 2021;58(3):182–187. <https://doi.org/10.1053/j.seminhematol.2021.07.001>.
78. Te Velthuis AJ, van den Worm SH, Sims AC, et al. Zn²⁺ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog*. 2010;6(11):e1001176. <https://doi.org/10.1371/journal.ppat.1001176>.
79. Tang CF, Ding H, Jiao RQ, et al. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. *Eur J Pharmacol*. 2020;886:173546. <https://doi.org/10.1016/j.ejphar.2020.173546>.
80. Wallace TC. Combating COVID-19 and building immune resilience: a potential role for magnesium nutrition? *J Am Coll Nutr*. 2020;39(8):685–693. <https://doi.org/10.1080/07315724.2020.1785971>.
81. Landi F, Martone AM, Ciciarello F, et al. On behalf of Gemelli against COVID-19 post-acute care team. Effects of a new multicomponent nutritional supplement on muscle mass and physical performance in adult and old patients recovered from COVID-19: a pilot observational case-control study. *Nutrients*. 2022;14(11):2316. <https://doi.org/10.3390/nu14112316>.
82. Jurek JM, Castro-Marrero J. A narrative review on gut microbiome disturbances and microbial preparations in myalgic encephalomyelitis/chronic fatigue syndrome: implications for long covid. *Nutrients*. 2024;16(11):1545. <https://doi.org/10.3390/nu16111545>.
83. Rodríguez-Morán M, Guerrero-Romero F, Barragán-Zuñiga J, et al. Combined oral supplementation with magnesium plus vitamin D alleviates mild to moderate depressive symptoms related to long-COVID: an open-label randomized, controlled clinical trial. *Magnes Res*. 2024;37(3):49–57. <https://doi.org/10.1684/mrh.2024.0535>.
84. Iqbal FM, Lam K, Sounderajah V, et al. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. *eClinicalMedicine*. 2021;36:100899. <https://doi.org/10.1016/j.eclinm.2021.100899>.
85. Barrea L, Grant WB, Frias-Toral E, et al. Dietary recommendations for post-COVID-19 Syndrome. *Nutrients*. 2022;14(6):1305. <https://doi.org/10.3390/nu14061305>.
86. di Filippo L, Frara S, Nannipieri F, et al. Low vitamin D Levels are associated with long COVID syndrome in COVID-19 Survivors. *J Clin Endocrinol Metab*. 2023;108(10):e1106–e1116. <https://doi.org/10.1210/clinem/dgad207>.
87. Grant WB, Lahore H, McDonnell SL, et al. Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients*. 2020;12(4):988. <https://doi.org/10.3390/nu12040988>.
88. Townsend L, Dyer AH, McCluskey P, et al. Investigating the relationship between vitamin D and persistent symptoms following SARS-CoV-2 infection. *Nutrients*. 2021;13(7):2430. <https://doi.org/10.3390/nu13072430>.
89. Crowe FL, Steur M, Allen NE, et al. Plasma concentrations of 25-hydroxyvitamin D in meat eaters, fish eaters, vegetarians and vegans: results from the EPIC-Oxford study. *Public Health Nutr*. 2010;14(2):340–346. <https://doi.org/10.1017/s1368980010002454>.
90. Ebrahimzadeh-Attari V, Panahi G, Hebert JR, et al. Nutritional approach for increasing public health during pandemic of COVID-19: a comprehensive review of antiviral nutrients and nutraceuticals. *HPP*. 2021;11(2):119–136. <https://doi.org/10.34172/hpp.2021.17>.
91. Gielen E, Beckwée D, Delaere A, et al. Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. *Nutr Rev*. 2021;79(2):121–147. <https://doi.org/10.1093/nutrit/nuaa011>.
92. Bradbury J, Wilkinson S, Schloss J. Nutritional support during long COVID: a systematic scoping review. *J Integr Complement Med*. 2023;29(11):695–704. <https://doi.org/10.1089/jicm.2022.0821>.
93. Ochoa JB, Cárdenas D, Goiburu ME, Bermúdez C, Carrasco F, Correia MITD. Lessons learned in nutrition therapy in patients with severe COVID-19. *JPEN - J Parenter Enter Nutr*. 2020;44(8):1369–1375. <https://doi.org/10.1002/jpen.2005>.
94. Fernández-Quintela A, Milton-Laskibar I, Trepiana J, et al. Key aspects in nutritional management of COVID-19 patients. *J Clin Med*. 2020;9(8):2589. <https://doi.org/10.3390/jcm9082589>.
95. O'Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. *Nat Rev Immunol*. 2016;16(9):553–565. <https://doi.org/10.1038/nri.2016.70>.
96. Iddir M, Brito A, Dingo G, et al. Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 Crisis. *Nutrients*. 2020;12(6):1562. <https://doi.org/10.3390/nu12061562>.
97. Diabetes (India). National Diabetes Obesity and Cholesterol Foundation (NDOC), and Nutrition Expert Group, India. Balanced nutrition is needed in times of COVID19 epidemic in India: a call for action for all nutritionists and physicians. *Diabetes Metabol Syndr*. 2020;14(6):1747–1750. <https://doi.org/10.1016/j.dsx.2020.08.030>.
98. Turner KL, Moorige FA, Martindale R. Nutrition support for the acute lung injury/adult respiratory distress syndrome patient: a review. *Nutr Clin Pract*. 2011;26(1):14–25. <https://doi.org/10.1177/0884533610393255>.
99. Gasmí A, Tippairote T, Mujawdiya PK, et al. Micronutrients as immunomodulatory tools for COVID-19 management. *Clin Immunol*. 2020;220:108545. <https://doi.org/10.1016/j.clim.2020.108545>.
100. McCullough FS, Northrop-Clewes CA, Thurnham DI. The effect of vitamin A on epithelial integrity. *Proc Nutr Soc*. 1999;58(2):289–293. <https://doi.org/10.1017/s0029665199000403>.
101. Timoneda J, Rodríguez-Fernández L, Zaragoza R, et al. Vitamin A deficiency and the lung. *Nutrients*. 2018;10(9):1132. <https://doi.org/10.3390/nu10091132>.
102. Carr AC, Maggini S. Vitamin C and immune function. *Nutrients*. 2017;9(11):1211. <https://doi.org/10.3390/nu9111211>.
103. Maggini S, Pierre A, Calder PC. Immune function and micronutrient requirements change over the life course. *Nutrients*. 2018;10(10):1531. <https://doi.org/10.3390/nu10101531>.
104. Chang HK, Hou WS. Retinoic acid modulates interferon- γ production by hepatic natural killer T cells via phosphatase 2A and the extracellular signal-regulated kinase pathway. *J Interferon Cytokine Res*. 2015;35(3):200–212. <https://doi.org/10.1089/jir.2014.0098>.
105. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. *J Heart Lung Transplant*. 2020;39(5):405–407. <https://doi.org/10.1016/j.healun.2020.03.012>.
106. Haryanto B, Sukmasari T, Wintergerst E, et al. Multivitamin supplementation supports immune function and ameliorates conditions triggered by reduced air quality. *Vitam Min*. 2015;4(2):100128. <https://doi.org/10.4172/2376-1318.1000128>.
107. Naidu SAG, Clemens RA, Naidu AS. SARS-CoV-2 infection dysregulates host iron (Fe)-redox homeostasis (Fe-RH): role of feredox regulators, ferroptosis inhibitors, anticoagulants, and ironchelators in COVID-19 control. *J Diet Suppl*. 2023;20(2):312–371. <https://doi.org/10.1080/19390211.2022.2075072>.
108. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. *Br Med J*. 2021;374:n1648. <https://doi.org/10.1136/bmj.n1648>.
109. Bolat E, Eker F, Kaplan M, et al. Lactoferrin for COVID-19 prevention, treatment, and recovery. *Front Nutr*. 2022;9:992733. <https://doi.org/10.3389/fnut.2022.992733>.
110. Campione E, Cosio T, Rosa L, et al. Lactoferrin as protective natural barrier of respiratory and intestinal mucosa against Coronavirus infection and inflammation. *Int J Mol Sci*. 2020;21(14):4903. <https://doi.org/10.3390/ijms21144903>.
111. Redel AL, Miry F, Hellemans ME, et al. Effect of lactoferrin treatment on symptoms and physical performance in long COVID patients: a randomised, double-blind, placebo-controlled trial. *ERJ Open Res*. 2024;10(4):31–2024. <https://doi.org/10.1183/23120541.00031-2024>.
112. Lim HX, Khalid K, Abdullah ADI, et al. Subphenotypes of Long COVID and the clinical applications of probiotics. *Biomed Pharmacother*. 2025;183:117855. <https://doi.org/10.1016/j.biopha.2025.117855>.
113. Batista KS, de Albuquerque JG, Vasconcelos MHA, et al. Probiotics and prebiotics: potential prevention and therapeutic target for nutritional management of COVID-19? *Nutr Res Rev*. 2023;36(2):181–198. <https://doi.org/10.1017/S0954422421000317>.
114. Zhang D, Li S, Wang N, et al. The cross-talk between gut microbiota and lungs in common lung diseases. *Front Microbiol*. 2020;11:301. <https://doi.org/10.3389/fmicb.2020.00301>.
115. Ettinger G, MacDonald K, Reid G, Burton JP. The influence of the human microbiome and probiotics on cardiovascular health. *Gut Microbes*. 2014;5(6):719–728. <https://doi.org/10.4161/19490976.2014.983775>.
116. Baud D, Dimopoulou Agri V, Gibson GR, et al. Using probiotics to flatten the curve of coronavirus disease COVID-2019 pandemic. *Front Public Health*. 2020;8:186. <https://doi.org/10.3389/fpubh.2020.00186>.
117. Zhou Y, Zhang J, Zhang D, et al. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. *J Microbiol*. 2021;59(10):941–948. <https://doi.org/10.1007/s12275-021-1206-5>.
118. Martinez FO, Combes TW, Orsenigo F, Gordon S. Monocyte activation in systemic Covid-19 infection: assay and rationale. *EBioMedicine*. 2020;59:102964. <https://doi.org/10.1016/j.ebiom.2020.102964>.
119. Schwabenland M, Salié H, Tanevski J, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. *Immunity*. 2021;54(7):1594–1610.e11. <https://doi.org/10.1016/j.immuni.2021.06.002>.
120. Almutairi MM, Sivandzade F, Albekairi TH, Alqahtani F, Cucullo L. Neuroinflammation and its impact on the pathogenesis of COVID-19. *Front Med*. 2021;8:745789. <https://doi.org/10.3389/fmed.2021.745789>.
121. Thyé AY, Law JW, Tan LT, et al. Psychological symptoms in COVID-19 patients: insights into pathophysiology and risk factors of long COVID-19. *Biology*. 2022;11(1):61. <https://doi.org/10.3390/biology11010061>.

122. Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol*. 2017;14(8):491–502. <https://doi.org/10.1038/nrgastro.2017.75>.
123. Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. *Foods*. 2019;8(3):92. <https://doi.org/10.3390/foods8030092>.
124. Olaimat AN, Aolymat I, Al-Holy M, et al. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. *NPJ Sci Food*. 2020; 4:17. <https://doi.org/10.1038/s41538-020-00078-9>.
125. Din AU, Mazhar M, Waseem M, et al. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. *Biomed Pharmacother*. 2021;133:110947. <https://doi.org/10.1016/j.biopha.2020.110947>.
126. Zhang L, Xu Z, Mak JWY, et al. Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: an open-label pilot study. *J Gastroenterol Hepatol*. 2022;37(5):823–831. <https://doi.org/10.1111/jgh.15796>.
127. Beatrice M, Alessandro R, Bottaro F, et al. The Role of VSL#3 in the treatment of fatigue and other symptoms in long covid-19 syndrome: a randomized, double-blind, placebo-controlled pilot study. *DELong#3*. 2023. <https://doi.org/10.1101/2023.06.28.23291986>. Clinical trial NCT05874089.
128. Zhu J, Pitre T, Ching C, et al. Safety and efficacy of probiotic supplements as adjunctive therapies in patients with COVID-19: a systematic review and meta-analysis. *PLoS One*. 2023;18(3):e0278356. <https://doi.org/10.1371/journal.pone.0278356>.
129. Lau RI, Su Q, Lau ISF, et al. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis*. 2024;24(3):256–265. [https://doi.org/10.1016/S1473-3099\(23\)00685-0](https://doi.org/10.1016/S1473-3099(23)00685-0).
130. Santinelli L, Laghi L, Innocenti GP, et al. Oral Bacteriotherapy Reduces the occurrence of chronic fatigue in COVID-19 patients. *Front Nutr*. 2022;8:756177. <https://doi.org/10.3389/fnut.2021.756177>.
131. Thomas R, Aldous J, Forsyth R, et al. The influence of a blend of probiotic Lactobacillus and prebiotic inulin on the duration and severity of symptoms among individuals with Covid-19. *Infect Dis Diag Treat*. 2021;5:182. <https://doi.org/10.29011/2577-1515.100182>.
132. Kharaeva Z, Shokarova A, Shomakhova Z, et al. Fermented *Carica papaya* and *Morinda citrifolia* as perspective food supplements for the treatment of post-COVID symptoms: randomized placebo-controlled clinical laboratory study. *Nutrients*. 2022;14(11):2203. <https://doi.org/10.3390/nu14112203>.
133. Noce A, Marrone G, Di Lauro M, et al. Potential anti-inflammatory and anti-fatigue effects of an oral food supplement in long COVID patients. *Pharmaceuticals*. 2024; 17(4):463. <https://doi.org/10.3390/ph17040463>.
134. Jolliffe DA, Holt H, Greenig M, et al. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). *Br Med J*. 2022;378: e071230. <https://doi.org/10.1136/bmj-2022-071230>.
135. Sinopoli A, Sciurri A, Isonne C, et al. The efficacy of multivitamin, vitamin A, vitamin B, vitamin C, and vitamin D supplements in the prevention and management of COVID-19 and long-COVID: an updated systematic review and meta-analysis of randomized clinical trials. *Nutrients*. 2024;16(9):1345. <https://doi.org/10.3390/nu16091345>.
136. Charoenporn V, Tungsukruthai P, Teacharushatak P, et al. Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: a randomized controlled trial. *Psychiatr Clin Neurosci*. 2024;78(10):595–604. <https://doi.org/10.1111/pcn.13716>.
137. Fernandes AL, Sales LP, Santos MD, et al. Persistent or new symptoms 1 year after a single high dose of vitamin D₃ in patients with moderate to severe COVID-19. *Front Nutr*. 2022;9:979667. <https://doi.org/10.3389/fnut.2022.979667>.
138. Tehrani S, Mahmoudnejad N, Ahmadi Asour A, et al. Efficacy of thiamine (Vitamin B1) on post-acute COVID-19 syndrome: an open-label, randomized, controlled trial. *Arch Clin Infect Dis*. 2024;19(5):e144280. <https://doi.org/10.5812/archcid-144280>.
139. Chung TW, Zhang H, Wong FK, et al. A pilot study of short-course oral vitamin A and aerosolised diffuser olfactory training for the treatment of smell loss in long COVID. *Brain Sci*. 2023;13(7):1014. <https://doi.org/10.3390/brainsci13071014>.
140. Gaylis NB, Kreychman I, Sagliani J, et al. The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID. *Front Nutr*. 2022;9:1034169. <https://doi.org/10.3389/fnut.2022.1034169>.
141. Calvani R, Gervasoni J, Picca A, et al. Effects of l-arginine plus vitamin C supplementation on l-arginine metabolism in adults with long COVID: secondary analysis of a randomized clinical trial. *Int J Mol Sci*. 2023;24(6):5078. <https://doi.org/10.3390/ijms24065078>.
142. Paulus MC, Kouw IWK, Boelens YFN, et al. Feasibility challenges in protein supplementation research: insights from the convalescence of functional outcomes after intensive care unit stay in a randomised controlled trial. *Clin Nutr*. 2025;46: 119–130. <https://doi.org/10.1016/j.clnu.2025.01.020>.
143. Marra AM, Giardino F, Anniballo A, et al. Beneficial effects on exercise capacity associated with a combination of lactoferrin, lysozyme, lactobacillus, resveratrol, vitamins, and oligoelements in patients with post-COVID-19 syndrome: a single-center retrospective study. *J Clin Med*. 2024;13(15):4444. <https://doi.org/10.3390/jcm13154444>.
144. Rossato MS, Brilli E, Ferri N, et al. Observational study on the benefit of a nutritional supplement, supporting immune function and energy metabolism, on chronic fatigue associated with the SARS-CoV-2 post-infection progress. *Clin Nutr ESPEN*. 2021;46:510–518. <https://doi.org/10.1016/j.clnesp.2021.08.031>.
145. Galluzzo V, Zazzara MB, Ciciarello F, et al. Fatigue in Covid-19 survivors: the potential impact of a nutritional supplement on muscle strength and function. *Clin Nutr ESPEN*. 2022;51:215–221. <https://doi.org/10.1016/j.clnesp.2022.08.029>.
146. Zahedipour F, Hosseini SA, Sathyapalan T, et al. Potential effects of curcumin in the treatment of COVID-19 infection. *Phytother Res*. 2020;34(11):2911–2920. <https://doi.org/10.1002/ptr.6738>.
147. Campbell JL. COVID-19: reducing the risk via diet and lifestyle. *J Integr Med*. 2023; 21(1):1–16. <https://doi.org/10.1016/j.joim.2022.10.001>.
148. Derosa G, Maffioli P, D'Angelo A, Di Piero F. A role for quercetin in coronavirus disease 2019 (COVID-19). *Phytother Res*. 2021;35(3):1230–1236. <https://doi.org/10.1002/ptr.6887>.
149. Del Bo C, Bernardi S, Cherubini A, et al. A polyphenol-rich dietary pattern improves intestinal permeability, evaluated as serum zonulin levels, in older subjects: the MaPLE randomised controlled trial. *Clin Nutr*. 2021;40(5):3006–3018. <https://doi.org/10.1016/j.clnu.2020.12.014>.
150. Park M, Choi J, Lee HJ. Flavonoid-rich orange juice intake and altered gut microbiome in young adults with depressive symptom: a randomized controlled study. *Nutrients*. 2020;12(6):1815. <https://doi.org/10.3390/nu12061815>.
151. Barrea L, Muscogiuri G, Frias-Toral E, et al. Nutrition and immune system: from the Mediterranean diet to dietary supplementary through the microbiota. *Crit Rev Food Sci Nutr*. 2021;61(18):3066–3090. <https://doi.org/10.1080/10408398.2020.1792826>.
152. Dharmalingam K, Birdi A, Tomo S, et al. Trace elements as immunoregulators in SARS-CoV-2 and other viral infections. *Indian J Clin Biochem*. 2021;36(4):416–426. <https://doi.org/10.1007/s12291-021-00961-6>.
153. Putri RWY, Noviana A, Huda M. Mediterranean diet: a nutritional suggestion for long covid management strategies – a literature review. *Int J Med Sci Clin Res*. 2024;4(2):277–285. <https://doi.org/10.47191/ijmscr/v4-i02-20>.
154. Liu RH. Dietary bioactive compounds and their health implications. *J Food Sci*. 2023;78(Suppl 1):A18–A25. <https://doi.org/10.1111/1750-3841.12101>.
155. Storz MA. Lifestyle adjustments in long-COVID management: potential benefits of plant-based diets. *Curr Nutr Rep*. 2021;10(4):352–363. <https://doi.org/10.1007/s13668-021-00369-x>.
156. Ostfeld RJ. Definition of a plant-based diet and overview of this special issue. *J Geriatr Cardiol*. 2017;14(5):315. <https://doi.org/10.11909/j.issn.1671-5411.2017.05.008>.
157. Glick-Bauer M, Yeh MC. The health advantage of a vegan diet: exploring the gut microbiota connection. *Nutrients*. 2014;6(11):4822–4838. <https://doi.org/10.3390/nu6114822>.
158. Chen Y, Zhang C, Feng Y. Medicinal plants for the management of post-COVID-19 fatigue: a literature review on the role and mechanisms. *J Tradit Complement Med*. 2024;15(1):15–23. <https://doi.org/10.1016/j.jtcm.2024.05.006>.
159. Karosanidze I, Kiladze U, Kirtadze N, et al. Efficacy of adaptogens in patients with long COVID-19: a randomized, quadruple-blind, placebo-controlled trial. *Pharmaceuticals (Basel)*. 2022;15(3):345. <https://doi.org/10.3390/ph15030345>.
160. Hawkins J, Hires C, Keenan L, Dunne E. Aromatherapy blend of thyme, orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: a randomized, double-blinded, placebo controlled clinical trial. *Compl Ther Med*. 2022;67:102823. <https://doi.org/10.1016/j.ctim.2022.102823>.
161. Teitelbaum J, Goudie S. An open-label, pilot trial of HRG80™ red ginseng in chronic fatigue syndrome, fibromyalgia, and post-viral fatigue. *Pharmaceuticals (Basel)*. 2021;15(1):43. <https://doi.org/10.3390/ph15010043>.
162. Zhang J, Xiaoju L, Xin L, et al. Mechanism of action of Bu Zhong Yi Qi decoction in the treatment of chronic fatigue syndrome based on network pharmacology and molecular docking. *PRMCM*. 2022;4:100139. <https://doi.org/10.1016/j.prmcm.2022.100139>.
163. Sanchis-Gomar F, Lavie CJ, Mehra MR, Henry BM, Lippi G. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. *Mayo Clin Proc*. 2020;95(7): 1445–1453. <https://doi.org/10.1016/j.mayocp.2020.05.006>.
164. Fernández-García JM, Romero-Secin A, Rubín-García M. Association between obesity and Long-Covid: a narrative review. *Semerger*. 2025;51(3):102390. <https://doi.org/10.1016/j.semerger.2024.102390>.
165. Zheng C, Chen XK, Sit CH, et al. Effect of physical exercise-based rehabilitation on long COVID: a systematic review and Meta-analysis. *Med Sci Sports Exerc*. 2024;56(1):143–154. <https://doi.org/10.1249/MSS.00000000000003280>.
166. Jimeno-Almazán A, Franco-López F, Buendía-Romero A, et al. Rehabilitation for post-COVID-19 condition through a supervised exercise intervention: a randomized controlled trial. *Scand J Med Sci Sports*. 2022;32(12):1791–1801. <https://doi.org/10.1111/sms.14240>.
167. Woods JA, Hutchinson NT, Power SK, et al. The COVID-19 pandemic and physical activity. *Sports Med Health Sci*. 2020;2(2):55–64. <https://doi.org/10.1016/j.smhs.2020.05.006>.
168. Hamilton MT. The role of skeletal muscle contractile duration throughout the whole day: reducing sedentary time and promoting universal physical activity in all people. *J Physiol*. 2018;596:1331–1340. <https://doi.org/10.1113/JP273284>.
169. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. *Am J Physiol Cell Physiol*. 2004;287:C834–C843. <https://doi.org/10.1152/ajpcell.00579.2003>.
170. Balchin R, Linde J, Blackhurst D, et al. Sweating away depression? The impact of intensive exercise on depression. *J Affect Disord*. 2016;200:218–221. <https://doi.org/10.1016/j.jad.2016.04.030>.
171. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(7):819–824. <https://doi.org/10.1001/jamacardio.2020.1096>.

172. Yang C, Jin Z. An acute respiratory infection runs into the most common noncommunicable epidemic—COVID-19 and cardiovascular diseases. *JAMA Cardiol.* 2020;5(7):743–744. <https://doi.org/10.1001/jamacardio.2020.0934>.
173. Boecker H, Sprenger T, Spilker ME, et al. The runner's high: opioidergic mechanisms in the human brain. *Cerebr Cortex.* 2008;18(11):2523–2531. <https://doi.org/10.1093/cercor/bhn013>.
174. Cheng X, Cao M, Yeung WF, Cheung DST. The effectiveness of exercise in alleviating long COVID symptoms: a systematic review and meta-analysis. *Worldviews Evidence-Based Nurs.* 2024;21(5):561–574. <https://doi.org/10.1111/wvn.12743>.
175. Joseph G. The impact of physical activity on long COVID symptoms among college students: a retrospective study. *Int J Environ Res Publ Health.* 2025;22(5):754. <https://doi.org/10.3390/ijerph22050754>.
176. Zheng C, Chen XK, Sit CH, et al. Effect of physical exercise-based rehabilitation on long COVID: a systematic review and meta-analysis. *Med Sci Sports Exerc.* 2024;56(1):143–154. <https://doi.org/10.1249/MSS.0000000000003280>.
177. Colas C, Le Berre Y, Fanget M, et al. Physical activity in long COVID: a comparative study of exercise rehabilitation benefits in patients with long COVID, coronary artery disease and fibromyalgia. *Int J Environ Res Publ Health.* 2023;20(15):6513. <https://doi.org/10.3390/ijerph20156513>.
178. Kerling A, Beyer S, Dirks M, et al. Effects of a randomized-controlled and online-supported physical activity intervention on exercise capacity, fatigue and health related quality of life in patients with post-COVID-19 syndrome. *BMC Sports Sci Med Rehabil.* 2024;16(1):33. <https://doi.org/10.1186/s13102-024-00817-5>.
179. Llurda-Almuzara L, Rodríguez-Sanz J, López-de-Celis C, et al. Effects of adding an online exercise program on physical function in individuals hospitalized by COVID-19: a randomized controlled trial. *Int J Environ Res Publ Health.* 2022;19(24):16619. <https://doi.org/10.3390/ijerph192416619>.
180. McDowell CP, Tyner B, Shrestha S, et al. Effectiveness and tolerance of exercise interventions for long COVID: a systematic review of randomised controlled trials. *BMJ Open.* 2021;15(3):e082441. <https://doi.org/10.1136/bmjopen-2023-082441>.
181. Ezzatvar Y, Ramírez-Vélez R, Izquierdo M, García-Hermoso A. Physical activity and risk of infection, severity and mortality of COVID-19: a systematic review and non-linear dose-response meta-analysis of data from 1 853 610 adults. *Br J Sports Med.* Published online August 22, 2022. <https://doi.org/10.1136/bjsports-2022-105733>.
182. Kaczmarczyk K, Ploszczyca K, Jaskulski K, Czuba M. Eight weeks of resistance training is not a sufficient stimulus to improve body composition in post-COVID-19 elderly adults. *J Clin Med.* 2025;14(1):174. <https://doi.org/10.3390/jcm14010174>.
183. Berry C, McKinnley G, Bayes H, et al. Resistance exercise therapy for long COVID: a randomized, controlled trial. *Preprint.* 2025. <https://doi.org/10.21203/rs.3.rs-6269439/v1>.
184. Peiris S, Izcovich A, Ordunez P, et al. Challenges to delivering evidence-based management for long COVID. *BMJ Evid Based Med.* 2023;28(5):295–298. <https://doi.org/10.1136/bmjebm-2023-112311>.
185. Suliman S, McClave SA, Taylor BE, et al. Barriers to nutrition therapy in the critically ill patient with COVID-19. *JPEN - J Parenter Enter Nutr.* 2022;46(4):805–816. <https://doi.org/10.1002/jpen.2263>.
186. Caccialanza R, Laviano A, Lobascio F, et al. Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): rationale and feasibility of a shared pragmatic protocol. *Nutrition.* 2020;74:110835. <https://doi.org/10.1016/j.nut.2020.110835>.